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I. INTRODUCTION
We are exposed, without our knowledge or consent, to a multitude
of chemicals every day. Chemicals are quietly leaching from con-
sumer products. We ingest and absorb these chemicals as they leach
from every day plastics and penetrate our skin through cosmetic and
other products. Recent studies have begun to expose both the extent
of chemical contamination in blood, urine, and breast milk, and the
extent to which consumer products may be contributing to this po-
tentially toxic soup. 1
This article takes a close look at the current federal regulatory re-
gime for cosmetic and child care products in particular, and chemical
regulation more generally, as well as recent legislative action in the
U.S. and Europe, and concludes with a discussion of possible regula-
tory solutions. This article focuses on toys and cosmetic products in
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1. See Environmental Working Group, http://www.ewg.org/
sites/humantoxome/ (last visited Feb. 15, 2009) (the Environmental Working
Group (EWG), a non-profit research organization, has completed 6 studies finding
a total of 455 industrial pollutants, pesticides and other chemicals in blood, urine
and breast milk of 72 people. Many of these chemicals are known carcinogens or
endocrine disruptors); see also Center for Disease Control, Third National Report
on Human Exposure to Environmental Chemicals (July 2005),
http://www.cdc.gov/exposurereport/pdf/thirdreport.pdf (identifying 148 manmade
substances in the bodies of U.S. citizens).
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particular because the regulatory control over these products is unbe-
lievably weak given the sensitive populations exposed, including
particularly children and women of reproductive age, and the non-
essential nature of these consumer products. The mother's chemical
body burden is shared with her fetus and the child may, in some
cases, be exposed to larger doses relative to body weight. 2 The sus-
ceptibility to a wide range of adverse effects is increased during de-
velopment, from preconception through adolescence, and develop-
mental exposures can lead to life long functional deficits and mani-
festations of increased disease risks. Potentially toxic exposure to
these sensitive populations can not be solved by regulating only toys
and cosmetics, but there are strong policy arguments for lowering
the acceptable threshold for risk and creating additional protection in
this regulatory context while we also work toward reforming our
chemical regulatory system as a whole in the United States.
In one study, researchers found an average of 200 industrial
chemicals and pollutants in umbilical cord blood from 10 babies
born in August and September of 2004. The chemicals identified
included perfluorochemicals used as stain and oil repellants in fast
food packaging, clothes, and textiles, including the Teflon chemical
PFOA, recently characterized as a likely human carcinogen, and
dozens of widely used brominated flame retardants and their toxic
by-products. Of the 287 chemicals detected, 180 cause cancer in
humans or animals, 217 are toxic to the brain and nervous system,
and 208 cause birth defects or abnormal development in animal
tests. 4 The dangers of pre- or post-natal exposure to this complex
mixture of carcinogens, developmental toxins, and neurotoxins have
never been studied. 5 In fact, no toxicity information at all is avail-
able for 78% of the 12,860 chemicals that are used in commerce in
2. Carl F. Cranor, Do You Want to Bet Your Children's Health on Post-
Market Harm Principles? An Argument For a Trespass or Permission Model For
Regulating Toxicants, 19 VILL. ENvTL. L. J. 251 (2008).
3. Id. at 258.
4. JANE HOULIHAN et al., BODY BURDEN: THE POLLUTION IN NEWBORNs 37-
50 (EWG 2005),
http://archive.ewg.org/reports-content/bodyburden2/pdf/bodyburden2_fmal-r2.pdf
(The study was spearheaded by the Environmental Working Group (EWG) in
collaboration with Commonweal. Researchers at two major laboratories identified
the chemicals after the umbilical cord blood of these 10 children was collected by
Red Cross after the cord was cut).
5. Id.
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quantities of more than one million pounds per year, and only mini-
mal toxicity information is available concerning the rest.
6
Of particular and increasing concern are endocrine disrupting
chemicals. Known or suspected endocrine disrupters are widespread
in the environment. A study done by the U.S. Department of Inte-
rior, U.S. Geological Survey, found a high incidence of intersex
(male fish exhibiting female characteristics) in smallmouth bass of
the Potomac River Basin. Scientists found pesticides, flame retar-
dants, and personal-care products containing known or suspected
endocrine-disrupting chemicals in both the fish and the river. High
intersex occurrence in aquatic species has also been documented at
other locations in the U.S. and in Europe. 7 The overall impact of
endocrine disrupting chemicals is unknown. There is evidence to
suggest that endocrine disrupting chemicals may be related to in-
creased rates of breast, prostate, and testicular cancer, among other
health problems including reduced fertility, birth defects, endome-
triosis (a disease of the uterus), malformed reproductive organs,
glandular dysfunction, and neurological disorders. 8 Today, 1 in 8
women are diagnosed with breast cancer. 9 For men, the risk of pros-
tate cancer is 1 in 6.10 In the United States, a woman's lifetime risk
of breast cancer has nearly tripled during the past four decades, with
less than 10% of cases occurring in women with a genetic predispo-
6. See John C. Dembach, The Unfocused Regulation of Toxic and Hazardous
Pollutants, 21 HARV. ENVTL. L. REV. 1, 28 (1997) (citing STEERING COMMITTEE
ON IDENTIFICATION OF Toxic AND POTENTIAL Toxic CHEMICALS FOR
CONSIDERATION BY THE NATIONAL TOXICOLOGY PROGRAM, NATIONAL RESEARCH
COUNCIL, TOXICOLOGY TESTING: STRATEGIES TO DETERMINE NEEDS AND
PRIORITIES 125 (1984)).
7. DOUGLAS B. CHAMBERS & THOMAS J. LEIKER, A RECONNAISSANCE FOR
EMERGING CONTAMINANTS IN THE SOUTH BRANCH POTOMAC RIVER, CACAPON
RIVER, AND WILLIAMS RIVER BASINS, WEST VIRGINIA, APR.-OCT. 2004 18 (2006),
http://pubs.usgs.gov/of/2006/1393/pdf/ofr20061393.pdf.
8. ENVIRONMENTAL PROTECTION AGENCY, INTERNATIONAL WORKSHOP ON
ENDOCRINE DISRUPTORS (Jan. 23-24, 1997), http://epa.gov/endocrine/Pubs/
smithrep.htm1; See also HOULIHAN et al., BODY BURDEN supra note 4, at 25-39;
Noah Sachs, Blocked Pathways: Potential Legal Responses to Endocrine Disrupt-
ing Chemicals, 24 COLUM. J. ENVTL. L. 289, 295 (1999).
9. Breast Cancer Fund, State of the Evidence 2008: The Connection Between
Breast Cancer and the Environment, http://www.breastcancerfund.org/site/
pp.asp?c=kwKXLdPaE&b=206137 (last visited Feb. 25, 2009).
10. American Cancer Society, What are the Key Statistics About Prostrate
Cancer?, http://www.cancer.org/docroot/CRI/content/CRI 2 4 IX What are_
the keystatistics for prostatecancer 36.asp?sitearea=' (last visited Feb. 15,
2009).
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sition for the disease." Prostate cancer rates have more than dou-
bled in a generation, rising 4.4 percent a year between 1973 and
1992.12 The incidence has declined since 1992, but it is still 2.5
times its 1973 rate.' 3 Prostate cancer is the most common cancer
among U.S. men, and the second most lethal. 14
Exposure to endocrine disrupting phthalates is an issue of increas-
ing concern. In 2003, the CDC confirmed widespread contamina-
tion, finding phthalates in virtually every person tested and the high-
est levels in children and women of reproductive age. 15 The bio-
logically active metabolites of DEHP, BBP, and DBP, which are
used in children's toys, were highest among children. 16 However,
according to the CDC's most recent report in 2005, phthalates are
found in virtually 100% of the population.' 7 Phthalates have been
linked to early puberty in girls, premature delivery, impaired sperm
quality and sperm damage, testosterone production, and testicular
cancer. 18 Phthalates have also been linked to the feminization of
boys. A recent government-funded study by Dr. Shanna Swan, a
professor of obstetrics and gynecology at the University of Roches-
ter, correlated prenatal phthalate exposure with a shortened anogeni-
tal distance (AGD) in male babies. 9 The higher the levels of phtha-
11. Breast Cancer Fund State of the Evidence 2006: What is the Connection
between Breast Cancer and the Environment, http://www.breastcancerfund.org/
site/pp.asp?c=kwKXLdPaE&b=1 370047 (last visited Feb. 15, 2009).
12. HOULIHAN ET AL., BODY BURDEN supra note 4, at 29 (Part of this increase
can be explained by better detection, but increased incidence has also been accom-
panied by an increase in mortality - which better detection cannot explain).
13. Id.
14. Id. at 30.
15. Env't Cal. Phtalates Overivew, https://www.environmentcalifomia.org/
environmental-health/stop-toxic-toys/phthalates (last visited Feb. 25, 2009) (citing
U.S. Centers for Disease Control and Prevention. 2003. Second National Report
on Human Exposure to Environmental Chemicals. Atlanta, GA: Centers for Dis-
ease Control and Prevention, National Center for Environmental Health, Division
of Laboratory Sciences).
16. Id.
17. Id. (citing U.S. Centers for Disease Control and Prevention. 2005. Third
National Report on Human Exposure to Environmental Chemicals. Atlanta, GA:
Centers for Disease Control and Prevention, National Center for Environmental
Health, Division of Laboratory Sciences).
18. Id.
19. Shanna H. Swan, Decrease in Anogenital Distance among Male Infants
with Prenatal Phthalate Exposure, 113 ENvTL HEALTH PERSP. Issue No. 8, Aug.
2005, at 1056-61, available at http://www.ehponline.org/members/2005/8100/
8100.pdf.
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lates in the mother during pregnancy, the more likely the researchers
were to find the shortened AGD.2  When this occurred, the boys
were more likely to have incomplete testicular descent and smaller
penises. The changes occurred at phthalate levels that have been
measured in about one quarter of women in the United States.
2
Bans for phthalates in products intended for children exist in Euro-
pean nations and Japan. Austria, Denmark, Finland, France, Ger-
many, Greece, Norway, and Sweden have all adopted bans.22 In
2005, the European Parliament made permanent an earlier temporary
emergency ban in place since the 1990s. 23 Several other nations,
including Argentina, Fiji, Mexico, and Japan have banned the use of
phthalates in toys and products intended for use by children. 24
Another chemical receiving particular attention is bisphenol-A
(BPA). BPA is used in the production of epoxy resins and polycar-
bonate plastic, food and drink packaging, and resins used as lacquers
to coat metal products such as food cans, bottle tops, and water sup-
ply pipes. 25 Human's are exposed to BPA at levels that cause prob-
lems in wildlife and laboratory animals, and scientists have con-
cluded that there is a great cause for concern with regard to the po-
tential for similar adverse effects in humans. 26  An expert panel
sponsored in 2006 by the National Institutes of Health, the U.S.
EPA, and Commonweal (a non-profit health and environmental re-
search group) explained that recent trends in human diseases relate
to adverse effects observed in experimental animals exposed to low
doses of BPA. As specific examples, the panel noted: the increase in
prostate and breast cancer, uro-genital abnormalities in male babies,
a decline in semen quality in men, early onset of puberty in girls,
20. Id.
21. Id.
22. Assemb. B. 1108, 2007 Cal. State Leg., (Cal. 2007), Bill Analysis, Senate
Envtl. Quality Comm. at 4, available at http://www.leginfo.ca.gov/pub/07-
08/bill/asrn/ab_1101-1150/ab_1108 cfa 20070712_131934_sen floor.html (to
add Chapter 11 (commencing with § 108935) to Part 3 of Division 104 of the
Health and Safety Code, relating to product safety).
23. Id.
24. Id.
25. S.F., CAL., ORDINANCE NO. 120-06 (2006).
26. Frederick S. vom Saal et al., Chapel Hill Bisphenol A Expert Panel Con-
sensus Statement: Integration of Mechanisms, Effects in Animals and Potential to
Impact Human Health at Current Levels of Exposure, 24 REPROD. TOXICOLOGY
131 (2007) available at http://www.environimentalhealthnews.org/newscience/
2007/2007-0801bpaconsensus.pdf.
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metabolic disorders including insulin resistant (type 2) diabetes and
obesity, and neurobehavioral problems such as attention deficit hy-
peractivity disorder (ADHD). The panel also expressed concern
that fetuses and children may be particularly susceptible to BPA ex-
posure and that irreversible developmental effects may not become
apparent until long after the exposure.2
8
Addressing widespread issues of chemical exposure in the United
States is difficult under the current toxic regulatory regime. With the
exception of manufacturers of pharmaceuticals, pesticides, and food
contact substances, manufacturers of most chemical substances in
consumer products are not required to do any toxicity testing before
selling their products to the public. Chemical regulation in con-
sumer products is delayed or indefinitely deferred as consumers bear
the risk until harm is well established and an effort is undertaken to
review the chemical or the product. This system puts a considerable
burden on governmental and also non-governmental entities. Add-
ing to the complexity, the post-market regulatory system is frag-
mented with separate federal agencies responsible for addressing
toxins in different types of products. Although the same chemical
may be contaminating our bodies from different sources of exposure,
there is no one regulatory authority that comprehensively considers
the question of cumulative exposure. Different divisions of the Food
and Drug Administration, operating under different enabling legisla-
tion, are responsible for food contaminants, drug ingredients, medi-
cal devices, and cosmetics. 29 Toys are under the regulatory author-
ity of the Consumer Product Safety Commission.
30
Following Europe's lead, advocacy groups in the U.S. have been
working to improve toy and cosmetic regulation. In 2005, the State
of California adopted the California Cosmetics Act, S.B. 484 (2005),
sponsored by the National Environmental Trust, Breast Cancer Ac-
tion, and Breast Cancer Fund, and supported by 42 other public
health, environmental, and civil rights advocacy groups. In passing
this legislation, the State identified inadequate federal regulation and
recent testing of cosmetic products in the United States and the
27. Id. §4.1.4.
28. Id.
29. See Food and Drug Administration, www.fda.gov./default.htm; see also 21
U.S.C.§ 341 et seq. (food); 21 U.S.C. §351 et seq. (drugs and devices); 21 U.S.C.
§ 361 (cosmetics).
30. Federal Hazardous Substance Act, 15 U.S.C.A. § 1261; Consumer Product
Safety Act, 15 U.S.C.A §2501.
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European Union, identifying substances known or suspected to cause
cancer and reproductive toxicity, including chemicals not identified
as ingredients on the product's label. 31 The California Cosmetics
Act requires manufacturers of cosmetic products to provide the state
with a list of its products that contain chemicals identified as causing
cancer or reproductive toxicity. The Act authorizes an investigation
of these cosmetic products, provides authority to require manufac-
turers to submit health effects data,32 and to regulate worker safety.
In 2006, the City of San Francisco adopted the first law in the U.S.
to restrict BPA and phthalates in children's toys. The Healthy Prod-
ucts Healthy Children ordinance banned the manufacture, sale, and
distribution of child care articles and toys intended for use by chil-
dren under age three containing bisphenol-A (BPA) and six phtha-
lates. 33 Bisphenol-A, and phthalates and are used in many products
designed for children, including but not limited to toys, pacifiers,
baby bottles and teethers. 34 Implementation of the ordinance was
temporarily suspended and the BPA portion removed following a
lawsuit alleging that the city was preempted by state and federal law
from engaging in this type of regulation.35 San Francisco later sus-
pended its ordinance due to legislative action at the state level.36 In
2007, California adopted AB 1108 prohibiting, after January 1,
2009, the manufacture, sale, or distribution in commerce of certain
toys and child care articles if those products contain types of phtha-
lates in concentrations exceeding 1/10 of 1%.37 Legislative efforts
31. CAL. HEALTH & SAFETY CODE § 111791 (West 2006).
32. Id. §111792.5.
33. S.F., CAL., ORDINANCE No. 120-06 (2006) (banning the phthalates DEHP,
DBP, BBP in concentrations exceeding 0.1 percent in any toy or child care prod-
uct, and DINP, DIDP, and DnOP in concentrations exceeding 0.1 percent in any
toy or child care article intended for use by a child under three years if the product
can be placed in the child's mouth).
34. Id.
35. Board of Supervisors, City & County of San Francisco, Apr. 17, 2007
Agenda, available at http://www.sfgov.org/site/bdsupvrspage.asp?id=58837.
36. S.F., CAL., HEALTH CODE art. 34, § 34.10 (2008) (suspending the ordi-
nance, but committing to continue a testing program).
37. CAL. HEALTH & SAFETY CODE §§ 108935-39 (West 2007) (prior to
amended on Apr. 25, 2007, the bill also included a prohibition on BPA. See
Official Cal. Legislative Information, http://www.leginfo.ca.gov/pub/07-08/bill/
asm/ab _101-1 150/ab_1108_bill_20070425_amended asm v98.html. Another
bill currently in the Cal. Leg., S.B. 1713, introduced on Feb. 22, 2008, to amend
§§ 108937 and 108939 of the Health and Safety Code would expand the restric-
tions and requirements for phthalates in toys to apply also to BPA).
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focused on both BPA and phthalates are underway in several states
and at the federal level.38 Congress recently banned children's toy
or child care articles that contain specified concentrations of speci-
fied phthalates. 
39
These recent legislative efforts have worked around, instead of
through, our current regulatory system for consumer product regula-
tion. Our existing system is deeply flawed, and this post-market
chemical-by-chemical approach to regulation is a long and burden-
some process, which leaves consumers unprotected in the interim.
There are too many chemicals of potential concern for us to continue
in this fashion. Serious questions of safety concerning other chemi-
cals on the market, as well as questions of safety about nanoparti-
cles, are coming to the forefront. Given the thousands of untested
chemicals on the market, we must move for more comprehensive
reform. The EPA reports that insufficient scientific data are avail-
able for most of the estimated 87,000 chemicals produced today to
allow for an evaluation of endocrine associated risks.4 1 EPA is cur-
rently developing an Endocrine Disruptor Screening Program
(EDSP), 42 but any results that may affect the consumer are far in the
38. E-mail from Margie Kelly, SAFER, to Rachael Rawlins (May 2, 2008) (on
file with author); see also Ban Poisonous Additives Act of 2008, H.R. 6228, 110th
Congress (would amend the Federal Food, Drug, and Cosmetic Act to deem to be
adulterated a food in a container that is composed, in whole or in part, of bisphenol
A or that can release bisphenol A into food); The BPA-Free Kids Act of 2008, S.
2928, 110th Congress (would ban BPA in children's products); Senate Panel
Takes On Plastics Additives in Consumer Products, E&E DAILY, May 12, 2008,
http://www.cancerpreventionsociety.org/ (last visited Feb. 25, 2009).
39. 15 U.S.C.A. § 2057 (2008).
40. Albert C. Lin, Size Matters: Regulating Nanotechnology, 31 HARV.
ENvTL. L. REv. 349 (2007); Carl F. Cranor, Do you Want to Bet your Children's
Health on Post-Market Harm Principles? An Argument for a Trespass or Permis-
sion Model for Regulating Toxicants, 19 VILL. ENvTL. L. J. 251 (2008) (including
a discussion of particular risk to fetuses and infants and identifying risks of
PBDE's, a class of flame retardants that have been used extensively in consumer
products since the 1960's); see also Assemb. B. 706, 2007 Cal. State Leg., (Cal.
2007) (which would have revised and extend the findings relating to fire retar-
dants, and would require all seating, bedding, and furniture products to comply
with certain requirements, including restrictions on brominated fire retardants or
chlorinated fire retardants).
41. Endocrine Disruptor Screening Program, http://www.epa.gov/scipoly/
oscpendo/index.htm (follow "Priority Setting Activities" hyperlink) (last visited
Feb. 27, 2009) [hereinafter EDSP].
42. Id; see also 21 U.S.C.A. § 346a(p) (West 2008) (Congress passed the
Food Quality Protection Act in 1996, requiring that EPA initiate EDSP to screen
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future. The program was created by the Food Quality Protection Act
in 1996 with deadlines for the EPA to develop screening procedures
within two years (by mid 1998) and to implement the program
within three years (by mid 1999). Even after having been spurred by
a lawsuit for failing to meet statutory deadlines, 43 EPA did not pub-
lish its final approach for selecting the initial 50 to 100 chemicals for
Tier 1 Screening until 2005. 44 In June 2007, EPA announced a draft
list that includes 73 chemicals to be screened under Tier 1 of the
program. In December 2007, EPA announced the draft policies and
procedures. 4 Once identified and tested, the chemicals will remain
on the market unless regulated under existing laws or new laws are
adopted.
II. FEDERAL REGULATION OF COSMETIC PRODUCTS IS LARGELY
ILLUSORY
Cosmetics are regulated by the federal Food and Drug Administra-
tion (FDA) under the Sherman Food, Drug and Cosmetic Act
(FDCA).46 Section 201(i) of the FFDCA defines a cosmetic as an
article (excluding soap) intended to be rubbed, poured, sprinkled,
sprayed on, introduced into, or otherwise applied to the human body
pesticide chemicals and environmental contaminants for their potential to affect
the endocrine systems of humans and wildlife. § 408 (p) of the Federal Food,
Drug, and Cosmetics Act (FFDCA) mandated EPA to "to determine whether cer-
tain substances may have an effect in humans that is similar to an effect produced
by a naturally occurring estrogen, or such other effects as [EPA] may designate");
EDSP; Chemical Selection Approach for Initial Round of Screening, 70 Fed. Reg.
56,449, 56,463 (Sept. 27, 2005) (Over the past few years, EPA has been working
to develop a priority setting approach. In 2002, EPA published a chemical selec-
tion approach for comment, and has now published a final approach for selecting
the initial 50 to 100 chemicals for Tier 1 Screening in Sept. 2005).
43. Settlement Agreement Between Plaintiffs and EPA, 5-7 (2001),
http://www.epa.gov/endo/pubs/settlement.pdf (In 1999 Natural Resources Defense
Council; The Breast Cancer Fund; CALPRIG Charitable Trust; Pesticide Watch
Education Fund; Pesticide Action Network; San Francisco By Area Physicians for
Social Responsibility; and United Farm Workers of America, and AFL-CIO filed a
complaint in the US District Court for the Northern District of California (Case
No. C-99-3701 CAL) against the US EPA. A Settlement Agreement with EPA
committing to "use best efforts" to meet specified deadlines was signed Jan. 9,
2001).
44. EDSP, supra note 41.
45. Id.
46. Codified at 21 U.S.C.§301 et seq.
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or any part thereof for cleansing, beautifying, promoting
attractiveness, or altering the appearance, and articles intended for
use as a component of any such articles. 47  "Cosmetics" include
skin-care creams, lotions, hairsprays, perfumes, lipsticks, fingernail
polishes, eye and facial makeup, permanent waves, hair colors,
deodorants, baby products (e.g., baby powder, baby oil, wipes), bath
oils, bubble baths, and mouthwashes.4 Regulation of these products
is minimal. Except for color additives,49 the FDA does not require
pre-market safety testing, review, or approval of chemicals in cos-
metic products before they are sold to the public. 50 The FDA has no
authority to require manufacturers to file health and safety data on
cosmetic ingredients or to order a recall of a dangerous cosmetic
product.5 1  The Federal statute does prohibit the adulteration or
misbranding 53 of any cosmetic in interstate commerce, and products
that contain a "poisonous or deleterious substance which may render
it injurious" pursuant to customary use; 54 or a "filthy, putrid, or de-
composed substance."5 5 However, these terms are not clearly de-
fined and, because the FDCA does not require cosmetic manufactur-
ers to submit any pre-market information to the agency,16 it has little
information upon which to take regulatory action.
Federal regulation does require that every ingredient in a cosmetic
product and every finished cosmetic product be adequately substan-
47. 21 U.S.C.A. § 321(i) (West 2007). However, sunscreen is generally regu-
lated as a drug. 21 C.F.R. § 700.35 (2008).
48. DEPT. OF HEALTH & HUMAN SERVICES, NANOTECHNOLOGY: A REPORT OF
THE U.S. FOOD AND DRUG ADMINISTRATION NANOTECHNOLOGY TASK FORCE,
July 25, 2007 at 27, available at http://www.fda.gov/nanotechnology/taskforce/
report2007.pdf.
49. Id. at 26 ("FDA regulates color additives under §§ 201(t) and 721 of the
FFDCA. Generally under these statutory provisions, any substance capable of
imparting color to any food, drug, cosmetic, or medical device, or the human body
is a color additive that requires premarket approval by FDA in the form of a
regulation listing (i.e., approving) the color additive for its intended uses.").
50. Cal. Safe Cosmetics Act of 2005, CAL. HEALTH & SAFETY CODE §
11179 1(1)(b) (West 2006) (identifying problems with federal regulation).
51. Id. § 111791(l)(c).
52. 21 U.S.C.A. § 361 (West 2008).
53. Id. § 362.
54. Id. § 361(a).
55. Id. § 361(b).
56. 21 C.F.R. §§ 710, 720, 730 (2008) (voluntary regulations requesting
registration but no toxicity information).
[VOL. XX
TEETHING ON TOXINS
tiated for safety prior to marketing, 57 but, in practice, this require-
ment has proven meaningless. The regulations state that any ingre-
dient or product whose safety has not been adequately substantiated
prior to marketing is misbranded unless it displays a warning state-
ment declaring, "the safety of this product has not been deter-
mined., 58 However, the FDA has not defined "safe," nor established
minimum testing requirements. 59 There is no requirement that in-
dustry report the basis for its conclusion that a product is "safe."
The cosmetic industry has established a panel, a nongovernmental
body funded by the industry's main trade association, called the
Cosmetic Ingredient Review (CIR). 60  However, CIR has reviewed
only 11 percent of the 10,500 ingredients that FDA has documented
in personal care products. 61 Through its own analysis, the Environ-
mental Working Group (EWG),62 a non-profit research organization,
found that products are on the market that violate the CIR's own safe
use recommendations to manufacturers, and that contain ingredients
that the CIR reviewed but found specifically lacked the data needed
63to substantiate safety. None of these products contained a warning
label. 64 In a review of 20,000 product labels in 2004 and 2005 the
57. Id. § 740.10(a).
58. Id.
59. See Envtl. Working Group [hereinafter EWG], Cosmetic Safety Database,
Consumer Update - FDA Admits Inability to Ensure the Safety of Personal Care
Products, http://www.cosmeticsdatabase.com/research/fdafails.php?nothanks=1
(last visited Feb. 27, 2009) [hereinafter Cosmetic Safety Database].
60. Id. See also CAL. HEALTH & SAFETY CODE § 111793.5 (West 2006).
61. Cosmetic Safety Database, supra note 59, (study based on a 2004 analysis
of the 2003 CIR Compendium by the EWG).
62. E-mail from Bill Walker, Vice President/West Coast, EWG & EWG Ac-
tion Fund, to Rachel Rawlins, Adjunct Professor, University of Texas at Austin
School of Architecture (May 23, 2008) (on file with author) (EWG is a non-profit
research organization with a team or scientists, computer programmers and media
strategists. EWG has 33 employees, and gets almost all of its money from chari-
table foundations that make grants in support of their work. A small amount
comes from contributions by individuals and a very small amount from compa-
nies. The EWG's 2005 budget was 3.7 million); see also ENvTL. WORKING
GROUP, ANNUAL REPORT (2005), www.ewg.org/files/EWG-AR2005.pdf; Cam-
paign for Safe Cosmetics, Contact Us, http://www.safecosmetics.org/contact/ (last
visited Oct. 12, 2008).
63. Cosmetic Safety Database, supra note 59 (study based on a 2004 analysis
of the 2003 CIR Compendium by the EWG). See also CAL. HEALTH & SAFETY §
11 1793.5(a)(2) (West 2006) (citing the 2004 analysis of the 2003 CIR Compen-
dium by the EWG).
64. See Cosmetic Safety Database, supra note 59.
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EWG did not find a single warning. In fact, warning statements are
rare, possibly nonexistent, on cosmetic products.65 Yet, in response
to a petition by the EWG, the FDA has refused to take enforcement
action, stating that the industry panel recommendations are insuffi-
cient evidence to determine if ingredients are safe and that it lacks
sufficient information to determine whether or not the ingredients
were adequately substantiated for safety.
66
Only 11 percent of the ingredients used in cosmetic products have
been tested for safety, 67 and many existing known carcinogens and
endocrine disruptors have been found in cosmetic products. An
EWG study found that 80 percent of all cosmetic products may be
contaminated with one or more recognized cosmetic impurities that
are linked to cancer and other health concerns and often readily
penetrate the skin.68 Although the FDA has taken the position that
the concentrations are not at levels to be a cause for concern, 69 re-
searchers found one carcinogen, 1, 4 Dioxane, in 57% of all baby
soaps and 34% of all baby lotions.7 ° Another study found endocrine
65. Id.
66. See id. (In June 2004, the EWG submitted a cosmetic safety petition to the
Food and Drug Administration challenging the claim that products were substanti-
ated for safety and requesting a warning label for products containing ingredients
that were contraindicated for the product use (for example, skin creams with in-
gredients for which the industry review panel concluded the ingredient should not
contact the skin) and products containing ingredients that the industry panel con-
cluded lacked the safety data needed to support a finding of safety. In the FDA's
September 2005 response to this petition, the agency replied that it could not take
action against these products, because it lacked the information to determine
whether or not the ingredients were adequately substantiated for safety, or were
causing acute injury. The FDA took the position that the industry panel recom-
mendations were not sufficient evidence to determine if ingredients are safe).
67. BREAST CANCER FUND, STATE OF THE EVIDENCE: THE CONNECTION
BETWEEN BREAST CANCER AND THE ENVIRONmENT 79 (Janet Gray ed., 5th ed.
2008) available at http://www.breastcancerfund.org/site/pp.asp?c=kwKXLdPa
E&b=206137 (follow "Download PDF" hyperlink) [hereinafter State of the Evi-
dence 2008].
68. EWG, EWG Research Shows 22 Percent of all Cosmetics may be Con-
taminated with Cancer-causing Impurities, Feb. 8, 2007, http://www.ewg.org/
node/21286 (last visited Feb. 26, 2009) (finding that 22 percent of all products
may be contaminated with 1,4-dioxane, but also discussing broader contamination
with other toxins).
69. U.S. Food and Drug Admin., Center for Food, Safety & Applied Nutrition,
1,4-Dioxane, July 3, 2007, http://www.cfsan.fda.gov/-dms/cosdiox.html (last
visited Feb. 26, 2009) [hereinafter Center for Food, Safety & Applied Nutrition].
70. EWG, supra note 68.
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disrupting chemicals phthalates in more than 70% of health and
beauty products tested, including popular brands of shampoo, de-
odorant, hair mouse, face lotion and every single fragrance tested.7'
A study in Europe found phthalates in nearly 80% of products.
7 2
In the FDA's own study, a survey of 48 consumer cosmetic prod-
ucts, including hair care products, deodorants, lotions and creams,
nail products, fragrances, and body washes, most products were
found to contain at least one phthalate ester.73 However, based on
the available exposure and toxicity data, the FDA concluded that
there is insufficient data to conclude that a human health hazard ex-
ists from exposure to phthalate esters from cosmetic products. 74 The
FDA explains that, although the CDC survey report in 2001 noted
elevated levels of phthalates excreted by women of child-bearing
age, neither it nor the other data reviewed by FDA established an
association between the use of phthalates in cosmetic products and a
health risk.75 The FDA dismissed an article from the American
Academy of Pediatrics that reported that infants exposed to infant
care products, specifically baby shampoos, baby lotions, and baby
powder, showed increased levels of phthalate metabolites in their
urine.76 Researchers found a strong association between several
phthalates and infant care products that are applied dermally and
therefore concluded that this is a major source and route of exposure
for infant phthalate exposure. Nevertheless, the FDA explained that
it did not establish an association between these findings and any
health effects, and that the levels of phthalates (if any) in the infant
care products were not determined.77
We know that phthalate exposure has been correlated with prema-
ture breast development, sperm damage in men and, changes in the
71. JANE HOULIHAN ET AL., NOT Too PRETTY: PHTHALATES, BEAUTY
PRODUCTS & THE FDA 5 (2002),
http://www.safecosmetics.org/docUploads/NotTooPrettyr51 .pdf.
72. JOSEPH DIGANGI, & HELENA NORIN, PRETTY NASTY - PHTHALATES IN
EUROPEAN COSMETIC PRODUCTS 6 (2002), http://www.safecosmetics.org/
docUploads/Prettynasty.pdf (last visited Feb. 26, 2009).
73. See FDA, Center for Food, Safety & Applied Nutrition, Phthalates and
Cosmetic Products (Feb. 7, 2008), http://vm.cfsan.fda.gov/--drs/cos-phth.html.
(last visited Feb. 26, 2009).
74. Id.
75. Id.
76. Id. (citing Sheela Sathyanarayana et al., Baby Care Products: Possible
Sources of Infant Phthalate Exposure, 121 PEDIATRICS 260 (2008)).
77. Id.
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anatomy and size of genitalia in male babies.78 We also know that
plithalates disrupt sexual development in male rates, resulting in un-
descended testicles and reduced testosterone production, and can
cause reproductive and developmental toxicity, including adverse
effects on the developing skeletal system in rats.79 We know that the
U.S. population is contaminated with phthalates, 80 and that health
affects are likely to also occur in humans. 8 ' What we don't know is
the exact extent to which cosmetics products are contributing to the
phthalate contamination of people. Historically, diet has been con-
sidered the major source of phthalate exposure in the general popula-
tion, but all sources, pathways, and their relative contributions to
human exposures are not well understood.82 Cosmetics, and other
products may result in significant but poorly quantified human expo-
sures to dibutyl phthalate, diethyl plithalate, or dimethyl phthalate
8 3
Significant data gaps make it difficult to identify with certainty, the
various sources, exposure pathways and their relative contributions
to phthalates exposure levels in the general population.84
The FDA did not eliminate the possibility that cosmetic products
pose a significant human health risk. 85 However, the FDA made it
clear that it is looking for "compelling evidence" before it will take
action to protect consumers for the uncertain risk posed by phtha-
lates.86 Under this system, not only must the consumer bear the risk
pending development of further data, but that risk is not disclosed.
Current labeling requirements are inadequate to inform the consumer
as to the risk posed by phthalates or other potentially toxic ingredi-
ents. FDA requires an ingredient declaration on the cosmetic prod-
ucts sold at the retail level to consumers,8 7 labels are generally re-
78. James Bothwell, Toy Story: Timeout for Phthalates, 39 MCGEORGE L.
REv. 551, 557-60 (2008) (summarizing evidence on phthalates).
79. Id.
80. See supra note 15.
81. Center for Food, Safety & Applied Nutrition, supra note 69.
82. See Ted Schettler, Human Exposure to Phthalates Via Consumer Products,
29 INT'L J. ANDROLOGY 134 (2006).
83. Id.
84. Id. at 137.
85. See J.C. Hubinger & D.C. Havery, Analysis of Consumer Cosmetic Prod-
uctsfor Phthalate Esters, 57 J. OF THE SOC'Y OF COSMETIC CHEMISTS 127 (2006),
abstract available at http://www.ncbi.nlm.nib.gov/pubmed/16688376.
86. Center for Food, Safety & Applied Nutrition, supra note 69.
87. 15 U.S.C.S. § 1454(c) (2008).
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quired to include ingredient lists, 88 and may be unlawful if the label
or container is false or misleading.89 However, federal law exempts
chemicals that qualify as trade secret and those used as fragrances or
flavoring from being identified as ingredients on the labels of cos-
metic products. 90 Laboratory analyses of cosmetic products sold in
California found products that contain substances known to or likely
to cause cancer or reproductive toxicity and not identified as an in-
gredient on the product's label.91 Further, the labeling requirements
do not apply to products used exclusively by professionals (i.e., in
salons). 92 However, even if ingredient labeling was complete, it
would still be inadequate to inform the consumer as to the risk posed
by the chemicals identified. That this information is desired by the
consumer is reflected in the fact that EWG's cosmetic safety data-
base, Skin Deep, 93 gets one million product searches per month.
94
The database matches ingredients in more than 25,000 products
against 50 toxicity and regulatory databases. 95 After entering the
name of a product, the website system will identify ingredients,
provide basic toxicity information and a product rating on a 1-10
scale for safety. On the website, the EWG asks and answers the
88. See Center for Food, Safety and Applied Nutrition, Cosmetic Labeling. An
Overview, http://www.cfsan.fda.gov/-dms/cos-lab4.html (last visited Feb. 26,
2009) (noting the FDA regulates cosmetic labeling under the authority of both the
Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Fair Packaging and
Labeling Act (FPLA). If the product is sold on a retail basis to consumers, even it
is labeled "For professional use only" or words to that effect, the ingredients must
appear on an information panel, in descending order of predominance); see also 21
U.S.C.S. § 362(b) (2008); 21 C.F.R. § 701.3 (2008).
89. 21 U.S.C.S. § 362(a) (2008).
90. See 15 U.S.C. § 1454(c)(3)(B) (2008) ("nothing . . . shall be deemed to
require that any trade secret be divulged"); see also 21 C.F.R. § 701.3(a) (2008)
(The label on each package of a cosmetic shall bear a declaration of the name of
each ingredient in descending order of predominance, except that fragrance or
flavor may be listed as fragrance or flavor. In lieu of the declaration of the name
of a confidential ingredient, the phrase "and other ingredients" may be used at the
end of the ingredient declaration); S.B. 484, § l(g), 2005 Leg., (Cal. 2005).
91. S.B. 484, § 1(g), 2005 Leg., (Cal. 2005).
92. 15 U.S.C.S. § 1459(a) (2008) (definition of consumer commodity); see
also Center for Food, Safety and Applied Nutrition, Phthalates and Cosmetic
Products, http://vm.cfsan.fda.gov/-dms/cos-phth.html (last visited Feb. 26, 2009).
93. See generally, Cosmetic Safety Database, supra note 59,
http://www.cosmeticsdatabase.com/ (last visited Feb. 26, 2009).
94. STACY MALKAN, NOT JUST A PRETrY FACE, THE UGLY SIDE OF THE
BEAUTY INDUSTRY 64 (New Society Publishers 2007).
95. Cosmetic Safety Database, supra note 59.
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question as to why a small nonprofit took on such a big project.
Their answer: "[b]ecause the FDA doesn't require companies to test
their own products for safety.9
96
III. HISTORY OF INACTION AT THE FEDERAL LEVEL
The lax state of federal cosmetics regulations is particularly trou-
blesome given that problems were identified almost 30 years ago in
a report by the 1978 General Accounting Office which recom-
mended that the FDA be given greater authority to regulate cosmetic
safety:
97
Cosmetics are being marketed in the United States which
may pose a serious hazard to health. Some contain toxic
ingredients which may cause cancer, birth defects or
other chronic toxic effects and contain contaminants
known to cause cancer in animals because exposure to
these ingredients can occur through skin absorption and
inhalation as well as oral ingestion. It is important that
the hazards posed by them be carefully assessed. 98
The report listed 125 ingredients used in cosmetics suspected of
causing cancer, 25 ingredients suspected of causing birth defects,
and 20 items suspected of adversely affecting the nervous system.
99
Almost 20 years later, responding to a bill intended to preempt state
regulations dealing with cosmetic safety, Senator Kennedy referred
to the 1978 report and pointed out that federal attention to cosmetic
safety remained wholly inadequate. He reported that less than 30
FDA employees regulate the $20 billion cosmetics industry, and
only 2 employees actually regulate cosmetic packaging and label-
ing. 100 He also cited a 1988 National Institute of Occupational
Safety and Health at NIH report to a congressional subcommittee
that analyzed 2,983 substances in cosmetics and found 884 cosmetic
96. Id.
97. 143 Cong. Rec. S8878, 8884 (Sept. 8, 1997) (statement of Sen. Kennedy).
98. Id.
99. 143 Cong. Rec. S9133, 9147 (Sept. 11, 1997) (statement of Sen. Kennedy).
100. 143 Cong. Rec. S8878, 8883 (Sept. 8, 1997); 143 Cong. Rec. S9133, 9150
(Sept. 11, 1997).
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ingredients had been reported to the Government as toxic sub-
stances. 101
In more recent years, the political climate has not improved. The
Bush administration spent considerable time and effort working on
behalf of the Chemical Industry. According to a U.S. House of Rep-
resentatives special interest case study, the Administration mounted
a campaign to block the efforts of the European Union to regulate
chemical companies. 102 The chemical and related manufacturing
sector provided $21,027,663 in campaign contributions in the 2000,
2002, and 2004 election cycles. Of this amount $16,543,081 was
provided to Republicans, and $912,207 was given to George W.
Bush. 103  Meanwhile, the Office of Cosmetics and Colors which
regulates toxins in cosmetic products has continued to have capacity
problems. Tooting a 2007 increase in funding, Pamela Bailey,
President and CEO of the Cosmetic, Toiletry and Fragrance Associa-
tion recently stated "our strong partnership with the FDA has been
put at risk because the Office of Cosmetics and Colors has shrunk to
an insufficient level.'1°4 Given that the increase in funding, reported
at $2 million, came on the heals of the FDA's Nanotechnology Task
Force Report, which expressed concern over the agency's ability to105
deal with the added complexity of nanotechnology, serious ques-
tions as to capacity remain.
IV. CALIFORNIA'S SAFE COSMETICS ACT, A STEP IN THE RIGHT
DIRECTION
The California Cosmetics Act requires manufacturers of cosmetic
products to provide the state with a list of products that contain
101. 143 Cong. Rec. S8846 (Sept. 5, 1997) (statement of Sen. Kennedy).
102. U.S. HOUSE OF REP. ON GOV'T REFORM - MINORITY STAFF SPECIAL
INVESTIGATIONS Div. FOR REP. HENRY A. WAXMAN, A SPECIAL INTEREST CASE
STUDY, THE CHEMICAL INDUSTRY, THE BUSH ADMINISTRATION, AND EUROPEAN
EFFORTS TO REGULATE CHEMICALS (Apr. 1, 2004), available at
http://oversight.house.gov/documents/20040817125807-75305.pdf.
103. Id. at 3 (citing Center for Responsive Politics, Chemical & Related Manu-
facturing: Long-Term Contribution Trends).
104. Skin Inc., CTFA Applauds Increased Funding for FDA Office of Cosmetics
and Colors, Aug. 14, 2007, http://www.skininc.com/skinscience/ingredients/
9154396.html (last visited Feb. 26, 2009).
105. FDA, NANOTECHNOLOGY TASK FORCE REPORT (July 2007),
http://www.fda.gov/nanotechnology/ (last visited Feb. 26, 2009).
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chemicals substances that are known or "reasonably anticipated" to
be a human carcinogen as well substances that have "some" or clear
evidence of adverse developmental, male reproductive, or female
reproductive toxicity effects in a report by an expert panel of the
National Toxicology Program's Center for the Evaluation of Risks to
Human Reproduction. 16 This list must include chemicals that are
contained in the product for purposes of fragrance or flavoring, and
those identified by the phrase "and other ingredients" and deter-
mined to be trade secret. 107 The Act authorizes an investigation of
these cosmetic products and provides authority to require manufac-
turers to submit health effects data. 108 In cases where the state de-
termines that products contain ingredients that the CIR has found are
not safe for the specific use indicated on the product, it requires re-
ferral of the findings to the Attorney General and the FDA for possi-
ble enforcement under the federal Food, Drug and Cosmetic Act. 109
It also requires that chemicals which are potentially toxic be regu-
lated for worker safety unless there is an affirmative written finding
that regulation is not necessary." 0
Except as it may work in conjunction with the Federal law, and
California's proposition 65, the Act does not provide any immediate
protection for consumers. Proposition 65,111 adopted by California
voters in 1986, requires warning labels on consumer products that
contain certain chemicals identified by various international, federal,
and state entities as either carcinogens or reproductive toxicants.
The list of regulated chemicals under Proposition 65 (about 700
chemicals are listed),1 12 is more limited than the chemicals that will
be identified under the California Cosmetics Act. Proposition 65's
warning requirement does not apply to chemicals only "reasonably
anticipated" to cause cancer for which reporting and testing may be
required under the Cosmetics Act, or those with only "some" evi-
106. CAL. HEALTH & SAFETY CODE § 11 1791.5(b)(4) (West 2006).
107. Id. § 111792(a).
108. Id. § 111792.5.
109. Id. § 111793.5(3).
110. Id.
111. CAL. HEALTH & SAFETY CODE § 25249.5 et seq. (West 2006).
112. STATE OF CAL. ENVTL PROTECTION AGENCY, OFFICE OF ENVTL HEALTH
AND HAZARD ASSESSMENT, SAFE DRINKING WATER AND TOXIC ENFORCEMENT
ACT OF 1986, CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR
REPRODUCTIVE TOXICITY (Sept. 12, 2008), http://www.oehha.ca.gov/prop65/
prop65_list/files/P65singleO9l2O8.pdf (last visited Feb. 26, 2009); see also 27 Cal.
Code of Reg. § 2700.
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dence adverse developmental, or reproductive toxicity. For chemi-
cals to be added to the Proposition 65 list they must be have been
"clearly shown through scientifically valid testing according to gen-
erally accepted principles to cause cancer or reproductive toxicity,"
identified by an authoritative body "as causing" cancer or reproduc-
tive toxicity, or already required by the state or federal government
to be labeled or identified as "causing" cancer or reproductive toxic-
ity. 113 California has now listed four phthalates on the Proposition
65 list. One phthalate, Di(2-ethylhexyl)phthalate (DEHP), a "known
carcinogen," has been on California's list since January 1988, and
three more "known to cause reproductive toxicity," butyl benzyl
phthalate (BBP), di-n-butyl phthalate (DBP), and di-n-hexyl phtha-
late (DnHP) were added in December 2005.114 The possibility of
listing BPA is under consideration. 15
Given the national effect of California's Proposition 65, other
states will likely benefit from California's effort even if they do not
adopt programs of their own. 116 Proposition 65 has been credited
113. CAL. HEALTH & SAFETY CODE § 25249.8 (warnings are required unless the
chemical is present in the product below a level that poses "no significant risk"
that is a level that causes no more than one excess lifetime case of cancer per
100,000 exposed individuals, and, for reproductive toxicants, 1/1000th of the
highest level at which the chemical has been shown to have no observable repro-
ductive effect. Id. § 25249.10. If a chemical is present in a product, the burden is
on industry to show that it does not exceed the allowable level. Id.
114. OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT, PROPOSITION
65 - CHANGES TO THE P-65 LIST (Dec. 12, 2005), http://www.oehha.org/
prop65/prop65_list/1202051ist.html (last visited Feb. 26, 2009) (chemicals become
"listed" based on a formal identification by an authoritative body, in this case the
National Toxicology Program Center for Evaluation of Risks to Human Reproduc-
tion (NTP-CERHR). Butyl benzyl phthalate (CAS No. 85-68-7), di-n-butyl phtha-
late (CAS No. 84-74-2), and di-n-hexyl phthalate (CAS No. 84-75-3) met the cri-
teria for reproductive toxicity for both males and females as well as developmental
toxicity as established under OEHHA).
115. OFFICE OF ENVIRONMENTAL HEALTH HAzARD ASSESSMENT,
ANNOUNCEMENT OF CHEMICALS SELECTED BY OEHHA FOR CONSIDERATION FOR
LISTING BY THE DEVELOPMENTAL AND REPRODUCTIVE TOXICANT IDENTIFICATION
COMMITTEE AND REQUEST FOR RELEVANT INFORMATION ON THE
DEVELOPMENTAL AND REPRODUCTIVE TOXICITY OF THESE CHEMICALS:
BISPHENOL A (Mar. 11, 2008), http://www.oehha.ca.gov/prop65/CRNRnotices/
state-listing/data_callin/extend031108.html (last visited Feb. 26, 2009).
116. Other states must consider additional preemption issues. Except for State
requirements adopted by a State public initiative or referendum enacted prior to
Sept. 1, 1997 (that is, Proposition 65), and those specifically approved after appli-
cation by the State, states are preempted from creating labeling and packaging for
cosmetic products that are different from or in addition to, or not otherwise identi-
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with stimulating significant consumer-product reformulation which,
in some cases, has been close to industry-wide with a nationwide
affect. 117 However, Proposition 65 does not fully resolve the issue
of consumer notification because of the limited class of chemicals to
which it applies and deficiencies in the allowable warning state-
ments. Unless there is certainty as to a chemical's harmful effects,
there is no law, state or federal, that requires consumer warnings.
Even for those chemicals where warning labels are required by
Proposition 65, consumers are often left in the dark. The regulations
establish "safe harbor" warning messages which have been used on
virtually all consumer product warnings. The safe harbor message
for consumer products states: "Warning: This product contains a
chemical known to the State of California to cause cancer birth de-
fects or other reproductive harm."' 18 The warning statement informs
individuals only that the product contains a chemical, not that use of
the product will expose them to a listed chemical. It leaves recipi-
ents unsure about whether there is an exposure, the identity of the
chemical, and the source of the exposure.
V. EUROPE'S LEAD, A MORE PRECAUTIONARY APPROACH
In 2004, the European Parliament prohibited the use in cosmetics
of certain chemicals that cause cancer, reproductive harm, or
mutagenicity. The substances are classified based on their intrinsic
properties without taking into account exposure. It is not necessary
to determine the exact contribution of cosmetic products to exposure,
or how much of a toxin might be considered "safe." The directive
prohibits the sale of personal care products that contain any of the
1,100 carcinogens, mutagens or reproductive toxins classified as
toxicants by the directive, 2 including di-methyl phthalate (DMP),
cal to Federal standards. 21 U.S.C.S. § 379 (2008). The preemption provision on
"packaging and labeling" specifically includes any State requirements relating to
public information or any other form of public communication. Id. According to
discussions on the Senate Floor, the provision was not intended to block any State
from otherwise exercising its police powers against unsafe cosmetic products. 143
Cong. Reg. S8880 (Sept. 8, 1997) (statement of Sen. Jeffords).
117. Clifford Rechtschaffen, The Warning Game: Evaluating Warnings Under
California's Proposition 65, 23 ECOLOGY L.Q. 303, 341 (1996).
118. Cal. Code Regs. Tit. 26, 22-12601(b)(4)(A)-(B)(1995).
119. Rechtschaffen, supra note 117, at 326.
120. STATE OF THE EVIDENCE 2008, supra note 67.
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benzylbutl phthalate (BBP); di-(2ethylhexyl) phthalate (DEHP). 12 1
The law creates three levels of certainty that the chemical hanns
human health: known, probable and possible. 122 The ban is abso-
lute for chemicals that fall in categories 1 and 2. For category 3, it is
conditional: a manufacturer may use the chemicals only if the Scien-
tific Committee finds the substances to be safe for use in cosmet-
ics. 123 The law also allows for some degree of risk assessment for
the presence of trace substances which are unavoidable and do not
cause damage to human health. 124 For example, traces of phthalates
that may leach unintentionally into cosmetic products through con-
tact with other products, materials or containers during production or
storage are allowed if they do not cause damage to human health.
125
Europe is currently considering a legislative proposal for change to
their cosmetic regulation. 126 The proposal would allow, subject to
rigid conditions, the use of a risk management regime that would
consider exposure and actual use of the substance and allow category
1 and 2 substances if they are determined to be safe by the Scientific
121. EUROPEAN COMMISSION, HEALTH & CONSUMER PROTECTION, SCIENTIFIC
COMMITTEE ON CONSUMER PRODUCTS, OPINION ON PHTHALATES IN COSMETIC
PRODUCTS (Mar. 21, 2007), available at
http://ec.europa.eu/health/phrisk/committees/04_sccp/docs/sccp_o_106.pdf.
122. COMMISSION OF THE EUROPEAN COMMUNITIES, WORKING PAPER: IMPACT
ASSESSMENT REPORT ON SIMPLIFICATION OF THE "COSMETICS DIRECTIVE" 16,
COM (May 2, 2008) available at http://www.europarl.europa.eu/registre/docs_
autresinstitutions/commission_europeenne/sec/2008/0117/COMSEC(2008)0117
_EN.pdf.
123. Council Directive 76/768/EEC, art. 4b, 1976 O.J. (L 262) available at
http://eur-lex.europa.euALexUriServ/site/en/consleg/1976/L/01976L0768-2006080
9-en.pdf ("The use in cosmetic products of substances classified as carcinogenic,
mutagenic or toxic for reproduction, of category 1, 2 and 3, under Annex I to Di-
rective 67/548/EEC shall be prohibited. . . . A substance classified in category 3
may be used in cosmetics if the substance has been evaluated by the SCCNFP and
found acceptable for use in cosmetic products.").
124. EUROPEAN COMMISSION, OPINION ON PHTHALATES IN COSMETIC
PRODUCTS, supra note 117, at 6 (citing the Cosmetic Directive (76/768/EC)) ("The
presence of traces of the substances listed in Annex II shall be allowed provided
that such presence is technically unavoidable in good manufacturing practice and
that it conforms with Article 2" (must not cause damage to human health)).
125. Id.
126. COMMISSION OF THE EUROPEAN COMMUNITIES, supra note 122, at 5;
European Parliament, The Legislative Observatory, Impact Assessment
http://www.europarl.europa.eu/oeil/OpenDetailFiche.do?ficheld=1445&language=
en (last visited Feb. 27, 2009).
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Committee for Consumer Products. 127 The change is proposed as an
exception to the principal rule of a ban. 128 The legislative impact
assessment report explains that because the automatic ban does not
consider exposure and actual use of the substance, it can lead to
situations of incoherence between different legislative regimes for
different products. As an example, the report discusses the possibil-
ity that Ethanol would be banned for use in consumer products (i.e.
perfume), but not in food and beverages.
The legislative proposal would also create a notification require-
ment and establish clear minimum safety standards for the cosmetic
safety assessments that are required before a product is placed on the
market. 129 Pre-market regulatory approval would not be required,
but industry would be required to actively report serious undesirable
effects. 130 The report explains this approach of reviewing products
as a whole would complement the ingredient-by-ingredient approach
which does not take into account interactions between ingredients.' 31
The assessment of individual substances also ties up considerable
regulatory resources. 132 The impact assessment further explains that
that there are safety-challenges lying ahead in the fast moving cos-
metic sector and the regulation of individual substances is too slow
to ensure safety. The EU industry places approximately 60,000 new
cosmetic formulations on the EU market every year. 133 The time
between identification of a substance which poses a risk, evaluation
of the risk, regulation through technical adaptation of the Cosmetics
Directive and actual changes in the composition of the product sold
to the consumer is very long (approximately five years). 134 The Sci-
entific Committee for Consumer Products already has an enormous
127. European Parliament, supra note 122.
128. Id. ("Additional safeguards shall ensure that risk-based regulation of these
substances would be the exception to the principal rule of a ban.").
129. Id.
130. COMMISSION OF THE EUROPEAN COMMUNITIES, Commission Staff Work-
ing Paper, Executive Summary, Impact Assessment Report on Simplification of the
"Cosmetics Directive" (2008) at 3 available at http://www.uni-
mannheim.de/edz/pdf/sek/ 2008/sek-2008-0118-en.pdf; Commission of the Euro-
pean Communities, supra note 122, at 38.
131. COMMISSION OF THE EUROPEAN COMMUNITIES, supra note 122, at 38.
132. Id. at 36.
133. Id. at 35.
134. Id. at 33.
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backlog, with almost 100 opinions on the safety of individual sub-
stances pending. 135
VI. POST MARKET FEDERAL REGULATION OF TOYS ALSO BURDENS
THE CONSUMER WITH POTENTIALLY SERIOUS UNDISCLOSED RISK
Toys, like cosmetics, are non-essential consumer products where
leaching chemical constituents may potentially affect a vulnerable
population. As with cosmetics, consumer product safety review is
generally limited to post-market review on a product by product ba-
sis with the difficult burden of proof as to toxicity and exposure on
the government. Safety considerations are also complicated by the
potential for multiple sources of exposure to the same chemical, and
possible unknown toxic synergistic effects between chemicals as
they commingle in the blood stream. As currently drafted, the Con-
sumer Product Safety Act (CPSA) 13 6 and the Federal Hazardous
Substances Act (FHSA) 137 have not been effective as vehicles for
regulating carcinogen, mutagens or reproductive toxins. The CPSC
has identified relatively few banned hazardous substances, its list of
banned toys and articles intended for use by children is short, and its
safety standards generally focus on such products with more obvious
hazards such as matchbooks, bicycle helmets, and swimming pool
slides. 138 Under the FHSA, the CPSC has authority to ban or regu-
late substances that are hazardous and that may cause substantial
injury or illness. 139 Under the CPSA, the CPSC may ban products
that create an "unreasonable risk of injury," when "no feasible con-
sumer product safety standard" can adequately address that risk. 140
Both the FHSA and the CPSA, however, impose significant proce-
dural and evidentiary burdens that require a high level of proof and
135. Id. at 37.
136. 15 U.S.C.A. § 2501 (West 2008) (note that the FHSA and the CPSA spe-
cifically exclude cosmetics from their regulatory reach. § 1261; § 2052(a)(1)).
137. § 1261.
138. James Bothwell, Toy Story: Timeout for Phthalates, 39 McGEORGE L.
REv. 551, 565 (2008) (citing Banned Toys and Other Banned Articles Intended for
Use by Children, 16 C.F.R. § 1500.18 (2007); Safety Standard for Matchbooks, 16
C.F.R. pt. 1202 (2007); Safety Standard for Bicycle Helmets, 16 C.F.R. pt. 1203
(2007); Safety Standard for Swimming Pool Slides, 16 C.F.R. pt. 1207 (2007)).
139. 15 U.S.C.A. § 1261(f)(1) (defining "hazardous substance"); § 1261(q)
(defining "banned hazardous substance").
140. § 2057.
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certainty before action may be taken to protect the unknowing con-
sumer from the risk of carcinogens, mutagens and reproductive tox-
ins.
Under the FHSA, the CPSC may ban toxic substances which have
the capacity to produce personal injury or illness through ingestion,
inhalation, or absorption through the body surface. 141 "Toxic" sub-
stances include known or probable human carcinogens, human neu-
rotoxins, and human developmental or reproductive toxicants.
142
However, the regulations exclude from the definition of "toxic"
those substances that are only "possible" carcinogens, human neuro-
toxins, and human developmental or reproductive toxicants. 143 In
the absence of human data, agents with "limited" evidence of car-
cinogenicity from animal studies fall into this category. 44  The
CPSC explains that "[t]his does not imply that the substances are or
are not carcinogens, only that the evidence is too uncertain to pro-
vide for a determination." 145 The burden of proof is on the CPSC to
demonstrate by "substantial evidence" that a substance is a known or
probable carcinogen, human neurotoxin, or human developmental or
reproductive toxin. 146 Before a toxic substance may be banned, the
FHSA also requires an elaborate rule making process with a formal
hearing applying the rules of evidence and the right to confront and
cross-examine witnesses. 147 The CPSC must include in its review
an analysis of the nature of the risk of injury, regulatory alternatives,
reasons why existing and proposed standards are inadequate, a de-
scription of the potential benefits and potential costs, an identifica-
tion of those likely to receive the benefits and bear the costs. 148 Fur-
ther, before the Commission can adopt a regulation, it must also
141. § 1261(g) (defining toxic).
142. 16 C.F.R. § 1500.3(c)(ii) (2008).
143. Id. See also 16 C.F.R. § 1500.135 (2008) (in defining "possible human
developmental toxicant," the CPSC does note that "it believes that data from well
planned animal studies are important to consider even though they may provide
only limited evidence of developmental toxicity." § 1500.135(c)(iii). However, the
significance of this statement is unclear as only known and probable human devel-
opmental or reproductive toxicants are within the definition of toxic for the pur-
poses of regulation).
144. 16 C.F.R. § 1500.135(a)(3) (2008).
145. Id.
146. 15 U.S.C.A. § 1262(a)(2) (requiring compliance with 21 U.S.C.A. §
371(f)).
147. Gulf S. Insulation v. Consumer Prod. Safety Comm'n, 701 F.2d 1137,
1149-50 (5th Cir. 1983) (citing 15 U.S.C.A. § 1262(a)(2)).
148. 15 U.S.C.A. §§ 1262(h)-(i).
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make a finding that a voluntary standard would be inadequate, and
that the regulation imposes the least burdensome requirement which
prevents or adequately reduces the risk of injury. 149
Under the Consumer Product Safety Act (CPSA), the Commission
has the authority to enact performance requirements, warnings or
instruction, 15 and product bans, 15' but again only after if it makes
affirmative findings, supported by substantial evidence.'I 2  Before
proceeding under the CPSA, the Commission must first find that the
risk could not be regulated sufficiently under the FHSA or that it is
in the public interest to proceed under the CPSA rather than the
FHSA.153 It must also bear the burden of proof to establish the
hazard and the likelihood of its reduction at reasonable cost. It must
be able to prove that the rule is reasonably necessary to eliminate or
reduce an "unreasonable risk of injury," that the rule imposes "the
least burdensome requirement" which prevents or adequately re-
duces the risk of injury, and that the benefits expected from the rule
bear a "reasonable relationship to its costs. '' 5  The inquiry as to
whether the potential effects are "unreasonable" involves a balancing
test. The regulation may issue if the severity of the injury that may
result from the product, factored by the likelihood of the injury,
offsets the harm the regulation imposes upon manufacturers and
consumers. 155 Although the rulemaking process is less formal under
149. § 1261(i)(2).
150. § 2056.
151. § 2057.
152. § 2060(c).
153. Gulf S. Insulation v. Consumer Prod. Safety Comm'n, 701 F.2d 1137,
1149-50 (5th Cir. 1983); but see Edward M. Fox, Note and Comment, Urea
Formaldehyde Foam Insulation: Defusing a Timebomb, 11 AM. J.L. & MED. 81
(1985) (questioning whether the Fifth Circuit was correct in its interpretation of §
2079(d)).
154. 15 U.S.C.A. § 2058(f)(3).
155. D.D. Bean & Sons Co. v. Consumer Prod. Safety Comm'n, 574 F.2d 643,
649 (1st Cir. 1978) (citing Aqua Slide 'N' Dive Corp. v. Consumer Prod. Safety
Comm'n, 569 F.2d 831, 838-39 (5th Cir. 1978)); see also, Forester v. Consumer
Prod. Safety, 559 F.2d 774, 786 n.14 (D.C. Cir. 1977) (clarifying the meaning of
"unreasonable" in 15 U.S.C.A. § 1261(s) in the defmition of "mechanical hazard"
explaining the requirement that the risk be "unreasonable" necessarily involves a
balancing test like that familiar in tort law: The regulation may issue if the severity
of the injury that may result from the product, factored by the likelihood of the
injury, offsets the harm the regulation itself imposes upon manufacturers and
consumers).
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the CPSA than the FHSA, 15 6 the burden of proof is still substantial.
Further, the Commission is again required to rely upon voluntary
consumer product safety standards whenever compliance with vol-
untary standards would eliminate or adequately reduce the risk of
injury. 157
As discussed above, under both the FHSA and the CPSA, the
CPSC must be able to support their findings as to toxicity with sub-
stantial evidence. Although it is not entirely clear whether the "sub-
stantial evidence" standard is actually stricter than the typical "arbi-
trary and capricious" standard of review of agency actions, some
courts have found the standard more demanding.' 58 In Gulf S.
Insulation v. Consumer Prod. Safety Comm 'n,159 in striking down a
consumer product safety rule banning Urea-Formaldehyde Foam
Insulation (UFFI), the court found that "[C]ongress put the
substantial evidence test in the statute because it wanted the courts to
scrutinize the Commission's actions more closely than an 'arbitrary
and capricious' standard would allow."160 The Gulf South Insulation
case exposes the burden on the CPSA and the relative risk allocation
between industry and the consumer. In that case, the court held that
the agency had failed to meet the burden of proof as to both acute
irritant effects and carcinogenicity of UFFI. UFFI is a thermal
insulation building material used that emits formaldehyde. The
levels are highest for several months after installation, and then
decrease gradually over a several-year period, eventually
approaching ambient levels. 161 Following the results of a Chemical
Industry Institute for Toxicology study linking formaldehyde
exposure at high levels to nasal cancer in rats, the agency established
156. GulfS. Insulation, 701 F.2d at 1149-50 (the rulemaking procedures man-
dated by The Consumer Product Safety Act, specifically 15 U.S.C.A. § 2057, and
the Federal Hazardous Substances Act, 15 U.S.C.A. §§ 1261-1276, differ substan-
tially. The Consumer Product Safety Act provides for an informal rulemaking. 15
U.S.C.A. § 2057. In contrast, the Federal Hazardous Substances Act requires a
formal hearing, complete with rules of evidence and the right to confront and
cross-examine witnesses. 15 U.S.C.A. § 1262(a)(2)).
157. 15 U.S.C.A. §§ 2056(b), 2058(d) (West 2008).
158. Holly E. Petitt, Comment, Shifting the Experiment to the Lab: Does EPA
Have a Mandatory Duty To Require Chemical Testing for Endocrine Disruption
Effects Under the Toxic Substances Control Act? 30 ENvTL. L. 413, 425 (2000)
(citations omitted).
159. 701 F.2d 1137.
160. Id. at 1142.
161. Id. at 1140.
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the Federal Panel on Formaldehyde, a group of sixteen scientists
from various government agencies, to evaluate the Chemical
Institute findings. The panel concluded that the Chemical Institute
study was valid and that formaldehyde should be presumed to pose a
carcinogenic risk to humans. However, in the face of conflicting
evidence submitted by the defendants and noting the element of
doubt with respect to formaldehyde levels, the court reasoned that
finding could not "authenticate the use of the study's results, and
only those results, to predict exactly the cancer risk UFFI poses to
man. 1 62  Although the court agreed with the agency that the
epidemiologic studies cited by the industry do not demonstrate
conclusively that formaldehyde poses no cancer risk to man, it
concluded that the commission failed to satisfy the substantial
evidence test. 163 In 1995, long after the conclusion of this failed
agency effort at regulation, the International Agency for Research on
Cancer (IARC) concluded that formaldehyde is a probable human
carcinogen. In a reevaluation of existing data in June 2004, the
IARC reclassified formaldehyde as a known human carcinogen.' 64
It is not possible to know if this case would have been resolved dif-
ferently if this information had been known previously, but it is clear
that burden of uncertainty weighed in favor of industry.
Under the FHSA, in addition to proving toxicity, the CPSA still
must also show that the product may cause substantial injury as used
by the consumer. There must be the potential that persons are ex-
posed to the substance, that the substance can enter the body, and
that there is a significant risk of an adverse health effect associated
with the customary handling, and use of the substance. 65 Under the
agency's guidelines, existence of an adverse health effect means that
such exposure is above the "acceptable daily intake" (ADI).166 Al-
though the regulations do provide for a margin of safety, determin-
ing the acceptable daily intake is rife with uncertainty. 67 Adding to
162. Id. at 1146.
163. Id. at 1147.
164. National Cancer Institute, Formaldehyde and Cancer: Questions and An-
swers, http://www.cancer.gov/cancertopics/factsheet/risk/formaldehyde (last vis-
ited Feb. 27, 2009).
165. Hazardous Substances and Articles; Admin. and Enforcement Regulations,
16 C.F.R. § 1500.135(d) (2008).
166. 16 C.F.R. § 1500.135(d)(4).
167. 16 C.F.R. § 1500.135(d)(4) (For carcinogens the ADI is that exposure of a
toxin that is estimated to lead to a lifetime excess risk of one in a million. The
regulations state that due to the difficulties in using a numerical risk assessment
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that uncertainty is the uncertainty of actual exposure levels. The
CPSC's decision on phthalates reflects the type of considerations
that may come into play in this approach. In 1998, the National En-
vironmental Trust and 11 other organizations petitioned the CPSC to
initiate a rulemaking to ban PVC from all toys and products intended
for children five years of age and under and issue a national advisory
on the health risks allegedly associated with PVC toys and prod-
ucts. 168  The Commission convened a Chronic Hazard Advisory
Panel to assess the health risks of exposure to diisononyl phthalate
(DINP), the plasticizer most commonly used in flexible vinyl
toys. 169 The Panel reviewed and commissioned studies measuring
migration of phthalates and estimating the time children spent
mouthing products containing phthalates. '70 It issued its final report
to the CPSC in June 2001.11 It determined an "acceptable" daily
intake of DINP, found that a child would have to mouth DINP-
plasticized toys for 75 minutes or more per day in order to pose a
possible risk, and that children do not mouth these toys for such ex-
tensive periods. The Commissioners denied the petition for rule-
making on February 26, 2003 finding that "[f]or the majority of chil-
dren, the exposure to DINP from DINP-containing toys would be
expected to pose a minimal to non-existent risk of injury,"' 72 and
noting that a survey of toys mouthed by children under the age of
three shows that not all soft plastic toys contain DINP. 173 This con-
clusion avoids consideration of the possibility of multiple sources of
method to determine risk for neurotoxicological or developmental/reproductive
toxicants, the Commission is using a safety factor of ten from the lowest no ob-
served effect level (NOEL) if the hazard is ascertained from human data, and 100
from the NOEL if the hazard is ascertained from animal data. If no NOEL can be
determined, a safety factor of 100 will be applied to the lowest observed effect
level (LOEL) where the hazard is ascertained with human data, and a safety factor
of one thousand from the LOEL where the hazard is ascertained with animal data).
See also, Howard Latin, Good Science, Bad Regulation, and Toxic Risk Assess-
ment, 5 YALE J. ON REG. 89, 119 (1988).
168. See Toy Indus. Ass'n, Inc., v. City and County of San Francisco, N.D.
Cal., case no. 06 7111, Complaint for Declaratory Judgment and Injunctive Relief,
at 8, citing Petition NO. HP 99-01.
169. Id. at 7, 14.
170. Id. at 10.
171. Id. at 12.
172. Id. at 17 (citing Letter from Todd Stevenson, Secretary, CPSC to Jeffrey
Becker Wise, Policy Director, Nat'l Envtl. Trust, citing a 2001 finding, and addi-
tional studies).
173. Id.
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exposure, the need to protect those children who may not behave like
the majority, and whether the value of these products is "worth" the
risk.
VII. HISTORY OF INACTION, AGAIN
As far back as 1977, the CPSC recognized that we need a product
assessment scheme for carcinogens.' 74 At that time, CPSC proposed
a "Cancer Policy" that called for classification of chemicals into four
categories based on the type of scientific data suggesting cancer-
causing potential: Category A was to include those substances for
which there are data from either human studies or long-term animal
testing; Category B was to include those substances for which there
are only data from short- term in-vitro studies; Category C sub-
stances were to include those for which there is only limited evi-
dence of a cancer risk, as well as chemicals belonging to classes or
families of chemicals known to cause cancer; and Category D was to
include substances previously classified by CPSC into one of the
other three classes but for which new data do not support the original
indication of potential carcinogenicity.
175
CPSC's policy is that it should not permit known carcino-
gens to be intentionally added to consumer products if
they can be absorbed, inhaled or ingested into the human
system. Substances in Category A which can enter the
human system will probably be banned. Substances in
Categories B and C will be tested further. Pending test
completion, CPSC may require point-of-sale warnings,
labeling or mandatory record-keeping by manufacturers
and distributors. CPSC will not take any regulatory ac-
tion on substances in Category D but will continue to
monitor any new information.
At the time of publication of this policy, CPSC had taken action
against four potential carcinogens: aerosols containing the chemical
vinyl chloride, the flame-retardant chemical TRIS in children's
174. Press Release, U.S. Consumer Prod. Safety Comm'n, CPSC Adopts Can-
cer Policy (June 8, 1978), available at http://www.cpsc.gov/CPSCPUB/PREREL/
prhtml78/78044.html.
175. Id.
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sleepwear, and artificial ashes and patching compounds containing
asbestos. Consumer products containing benzene had been proposed
to be banned. 176 That same year, 1977, Consumer Product Safety
Commission (CPSC) Chairman S. John Byington speaking before a
group of medical alumni, Byington said:
The nation must reach agreement on the validity of cer-
tain screening procedures for carcinogens, as well as pre-
market testing and analysis of scientific and socio-
economic trade-offs. More importantly, there must be
leadership not only within the government but also
among the American people to give this problem the pri-
ority attention it deserves.
177
No significant progress has been made to date. The Commission's
2005 staff of 446 was less than half its size in 1980,178 and its
regulatory list of banned hazardous substances remains short with
restrictions on chemical compounds concerning only carbon
tetrachloride, sodium and/or potassium hydroxide in liquid drain
cleaners, soluble cyanide salts, lead compounds, asbestos, and vinyl
chloride. 179 The Commission's workforce, as reported in 2007, had
shrunk fifteen percent since 2004, and, according to one of its
commissioners, it was in the midst of a dramatic "downsizing and
dismantling" in 2007.180
This year, with the recently enacted CPSC Reform Act18' there is a
change in direction. The CPSC Reform Act will give the
Commission a significant boost in funding and additional statutory
176. Id.
177. Press Release, U.S. Consumer Prod. Safety Comm'n, CPSC Chairman
Calls on Medical Profession To Support Nat'l Policy on Carcinogen (May 11,
1977), available at http://www.cpsc.gov/CPSCPUB/PREREL/prhtm177/
77047.html.
178. Albert Lin, Size Matters: Regulating Nanotechnology, 31 HARv. ENVTL.
L. REV. 349, 369 (2007), (citing SuSAN DUDLEY & MELINDA WARREN, UPWARD
TREND IN REGULATION CONTINUES: AN ANALYSIS OF THE U.S. BUDGET FOR
FISCAL YEARS 2005 AND 2006 21 tbl. A-3 (George Mason Univ., Wash. Univ.)
(2005).
179. 16 C.F.R. § 1500.17.
180. James Bothswell, Toy Story: Timeout for Phthalates, 39 MCGEORGE L.
REv. 551, 565 (2008) (citations omitted).
181. Consumer Product Safety Improvement Act of 2008, H.R. 4040, 110th
Cong. (2nd Sess. 2008).
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authority. The legislation addresses a broad range of issues, 182
however, it does not address the problems fundamental to toxic
substance regulation. The legislation will increase the
Commission's budget which will rise from its current $80 million to
$118 million starting in fiscal 2010, and growing to $136 million
over five years.' 83  It will also require the CPSC, subject to the
availability of appropriations, to increase by at least 500 the number
of its full-time employees and by at least 50 the number of its port-
of-entry and overseas production facility inspectors.' 84 Along with
this considerable increase, Congress recognized the need for
mandatory third party testing for children's products. 18 5 However,
the new testing rules apply only where there is already a Consumer
Product Safety Commission rule, ban, standard, or regulation already
in place. 186 Congress also moved to enact a direct statutory ban on
phthalates in children's products and child care articles, 187 but made
no structural changes to regulatory system for reviewing other toxins
in child care or other consumer products generally.
VIII. THE FEDERAL REGULATORY SYSTEM FOR CHEMICAL
REGULATION GENERALLY, THE Toxic SUBSTANCE CONTROL ACT IS
UNQUESTIONABLY INADEQUATE
Toxic Substances Control Act (TSCA) 188 was enacted by Congress
in 1976 to "regulate commerce and protect human health and the
environment by requiring testing and necessary use restrictions on
182. Id. (Among other provisions, it will reduce the permissible levels of lead
found in children's products, require third-party testing of certain types of
children's products, establish a publicly available and searchable database on the
safety of consumer products, provide whistleblower protection for industry
employees, and increase the maximum civil penalty for the violation of consumer
product safety standards).
183. Georgina Coolidge, Bush signs consumer bill to cut lead in toys, REUTERS,
Aug. 15, 2008, http://www.boston.com/news/nation/washington/articles/2008/
08/15/bushsigns consumer-bill-to cut lead in toys/ (last visited Feb. 27,
2009); H.R. 4040 § 201.
184. H.R. 4040, CRS Summary.
185. H.R. 4040 § 40.
186. Id. § 102.
187. Id.
188. Pub. L. No. 94-469, 90 Stat. 2003 (1976) (codified as amended at 15
U.S.C. §§ 2601-2692 (1988 & Supp. V 1993)) (regulations promulgated pursuant
to the Act are found at 40 C.F.R. Parts 702 through 775).
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certain chemical substances."' 189 For "chemical substances" within
TSCA's regulatory reach, but also possibly regulated by other stat-
utes, EPA must also first make a determination that it is in the public
interest to protect against a risk under TSCA as opposed to under
another Federal law (or laws) that it administers.' 90 TSCA's regula-
tory reach is also restricted with the specific exclusion of certain
chemical substances, including cosmetics and components of
cosmetics. 19 1 TSCA regulates the manufacture, use, and disposal of
other chemicals that pose a significant risk of injury to the
environment and human health. However, TSCA creates such bur-
densome factual and evidentiary requirements that it has proven
largely ineffective.
Under TSCA, chemical companies must only notify EPA of their
intent to manufacture or import new chemicals and to provide any
testing, environmental and health effects data that is available.
92
However, EPA estimates that most pre-manufacture notices do not
include test data of any kind, and only about 15 percent include
health or safety test data - such as acute toxicity of skin and eye irri-
tation data. 193 Chemical companies are not required to develop and
submit toxicity information to EPA unless the agency first promul-
gates a testing rule. 194 Except for chemicals produced in high vol-
umes and posing a substantial risk of exposure, 195 TSCA provides
the EPA with authority to impose testing requirements on chemicals
only if the EPA can demonstrate by substantial evidence that the
189. Id.
190. 15 U.S.C.S. § 2605(C) ("In making such a finding the Administrator shall
consider (i) all relevant aspects of the risk, as determined by the Administrator in
the Administrator's discretion, (ii) a comparison of the estimated costs of
complying with actions taken under this Act (15 U.S.C.S. §§ 2601 et seq.) and
under such law (or laws), and (iii) the relative efficiency of actions under this Act
[15 U.S.C.S. §§ 2601 et seq.] and under such law (or laws) to protect against such
risk of injury").
191. 15 U.S.C. § 2602(2)(B)(vi); 21 U.S.C.S. § 321 (defining cosmetics).
192. 15 U.S.C. § 2604(d)(1)(B).
193. Testimony before the Committee on Environment and Public Works, U.S.
Senate, Chemical Regulation: Actions are needed to improve the effectiveness of
EPA's chemical review program, GAO-06-1032T, at 8, April 2, 2006 (statement
of John B. Stephenson, Director, Natural Resources and Environment).
194. 15 U.S.C.S. § 2603 (2000).
195. 15 U.S.C. § 2603(a)(l)(B); see also High Productive Volume (HPV) Chal-
lenge, http://www.epa.gov/HPV/ (last visited Feb. 27, 2009) (involving voluntary
agreements between the EPA and manufacturers to test chemicals produced in
high volumes).
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existing data are "insufficient" to assess the chemical and the EPA
has a "more than theoretical" basis to suspect that the chemical "may
present" a risk or hazard. 196 Finalizing test rules can take 2 to 10
years and require the expenditure of substantial resources. 197 The
costly and time consuming burden of obtaining data is on EPA, not
the chemical companies. & EPA assesses production volume and
exposure using the pre-manufacture notices; however, chemical
company estimates of a production volume and anticipated uses do
not generally have to be amended accept in the few cases where EPA
promulgates a rule determining that a use of a chemical constitutes a
significant new use. 199 EPA has authority to promulgate rules which
require chemical companies to submit lists or copies of any existing
health and safety rules to EPA.20 ° Chemical companies must also to
report any information to EPA that reasonably supports a conclusion
that a chemical presents a substantial risk of injury to health or the
environment. 20 However, EPA has required testing of fewer than
200 of the 62,000 chemicals in commerce when EPA began review-
ing chemicals under TSCA in 1979.202
After obtaining test data, TSCA places the burden of proof on EPA
to show that a chemical poses an "unreasonable risk" before EPA
can act to regulate its production or use. 20 3 The substantial evidence
rule applies. 2°4 The test here is the same as that under the FHSA.
The requirement that the risk be "unreasonable" involves a balancing
test. "The regulation may issue if the severity of the injury that may
result from the product, factored by the likelihood of the injury, off-
196. Chemical Mfrs. Ass'n v. U.S. E.P.A., 859 F.2d 977 (D.C. Cir. 1988)
(Upholding a test rule and finding that, under § 4 of Toxic Substances Control Act
(15 U.S.C.S. § 2603), EPA is empowered to issue test rule on health grounds
where it finds "more-than-theoretical" basis for suspecting that chemical substance
in question presents unreasonable risk of injury to health, considering the toxicity
of the substance and human exposure).
197. General Acct. Office, Chemical Regulation, Comparison of U.S. and Re-
cently Enacted European Union Approaches to Protect against the Risks of Toxic
Chemicals, G.A.O. 07-825 (2007) at 9 (estimates by officials responsible for im-
plementing TSCA).
198. Id.
199. Statement of John B. Stephenson, supra note 193, at 3; see also 15 U.S.C.
§ 2604(a)(2); 40 C.F.R. § 721 pt. E.
200. 15 U.S.C.S. § 2607(d) (2008).
201. Id.
202. Statement of John B. Stephenson, supra note 193, summary of findings.
203. 15 U.S.C.S. § 2605 (2008).
204. Corrosion Proof Fittings v. E.P.A., 947 F.2d 1201, 1213 (5th Cir. 1991).
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sets the harm the regulation itself imposes upon manufacturers and
consumers." 20 5  EPA must also choose the least burdensome re-
quirement that will protect adequately against the risk.20 6
EPA's failed attempt to ban asbestos, a known carcinogen, exposes
the difficulty of satisfying the statutory prerequisites. In Corrosion
Proof Fittings v. Environmental Protection Agency,2 °7 the Fifth Cir-
cuit vacated EPA's asbestos rule due to insufficient data and calcula-
tions, as well as the difficulty of according weight to "unquantifi-
able" benefits. 20 8 The court required both costs and benefits to be
discounted, including benefits measured in terms of human lives
saved, and faulted EPA for equating the time of exposure with the
time of latent injury. 20 9 The court also found that EPA failed to
measure the costs and benefits over a long enough time frame.
EPA's quantitative analysis spanned only 13 years, leaving unquan-
tified the cost of injury to young workers who will still be at risk
210
more than thirty years after EPA's analysis period had ended.
Among other deficiencies, EPA was also faulted for failing ade-
quately consider improvements in the workplace, and to meet its
obligation to calculate how many lives a less burdensome regulation
would save, and at what cost.2 11 Of most concern to the Court was
EPA's failure to adequately evaluate less burdensome alterna-
tives. 2 12 Also important was its failure to adequately evaluate sub-
stitute products. Although unable to fully quantify the risks of
214possible alternatives, EPA had concluded that substitute fibers
appear to pose less hazard than this known carcinogen, that years
would likely pass before experimental toxicological data are avail-
able to quantify or adequately evaluate the possible health effects of
205. Id. at 1222.
206. 15 U.S.C.S. § 2605 (2008).
207. Corrosion Proof Fittings, 947 F.2d at 1201.
208. See Andrew Hanan, Note and Comment, Pushing the Environmental Regu-
latory Focus a Step Back: Controlling the Introduction of New Chemicals Under
the Toxic Substances Control Act, 18 AM. J. L. & MED. 395, 415 (1992) (detailed
analysis of decision).
209. Corrosion Proof Fittings, 947 F.2d at 1218.
210. Id. at 1218-19.
211. Id. at 1215.
212. Id. at 1229.
213. Id. at 1230.
214. Hanan, supra note 208, at 413 (citing 54 Fed. Reg. 29,481 (1989)) ("Regu-
latory decisions about asbestos which poses well-recognized, serious risks, should
not be delayed until the risks of all replacement materials are fully quantified.").
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substitutes, that it would take even longer to confirm any hazards,
the risks that would need to be evaluated are themselves evolving as
the industry is creating new substitutes, and the risks associated with
other fibers are easier to control because the diameter size can be
controlled. 215 Although noting that EPA did not have a duty to af-
firmatively seek out and test all possible substitutes, the court con-
cluded that substitutes identified by interested parties that may pre-
sent significant risks must be fully evaluated.2 6 The EPA's effort
failed under the substantial evidence test.
One commentator remarked: [i]t is entirely possible that, at one
level of practical scientific investigation, a reasonable conclusion
could be drawn that a risk exists and is potentially large. To go to
the next level of scientific investigation and actually calculate these
risks with precision, however, may be completely impractical.,
2 17
EPA reports that TSCA's legal standards for demonstrating unrea-
sonable risk are so high that they have generally discouraged EPA
from using its authorities to ban or restrict the manufacture or use of
existing chemicals.218 Since TSCA was enacted in 1976, EPA has
issued regulations under the act to ban or limit the production of only
five existing chemicals or groups of chemicals.219
IX. EUROPE'S LEAD, AGAIN A MORE PRECAUTIONARY APPROACH
The EU has recently revised its chemical control policy to create a
single system for the regulation of new and existing chemicals
through legislation known as Registration, Evaluation, and Authori-
zation of Chemicals (REACH). 220 Reach is based on the principle
that chemical companies - manufacturers, importers, and other enti-
ties in the supply chain - should ensure that the chemicals they
manufacture, place on the market, or use, do not adversely affect
215. Id. at 413-14 (citing 54 Fed. Reg. 29, 483).
216. Corrosion Proof Fittings, 947 F.2d at 1230.
217. Hanan, supra note 208, at 416.
218. Statement of John B. Stephenson, supra note 193, summary of findings.
219. Id. at 2-3 (noting that TSCA's approach to trade secrets is also problem-
atic. According to EPA officials, about 95% of the pre-manufacture notices for
new chemicals contain some information claimed as confidential); Id. at 26-27
(stating TSCA restricts EPA's ability to share confidential information even with
state officials or with officials of foreign governments. EPA may challenge confi-
dentiality claims, but doing so is resource intensive.).
220. Id.
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human health or the environment. 22 1 Under REACH, chemical
companies must obtain authorization to use chemicals that are listed
as chemicals of very high concern. Generally, to obtain such au-
thorization, chemical companies need to demonstrate that they can
adequately control risks posed by the chemical or otherwise ensure
that the chemical is used safely. Information requirements with reg-
istration will vary according to the production volume and suspected
toxicity of the chemical.22 The application for authorization must
also include an analysis of the technical and economic feasibility of
223using safer substitutes. The EU is generally required to grant an
authorization if the applicant meets the burden of demonstrating that
the risks from the manufacture, use or disposal of the chemical can
be adequately controlled. However, for certain very bio-
accumulative chemicals and certain other chemicals that are carcino-
gens or reproductive toxins, the chemical company must demon-
strate that the social and economic benefits outweigh the risks to
receive approval.224 REACH also places substantial restrictions on
the types of data that chemical companies may claim as confiden-
tial,2 and provides procedures for placing restrictions on chemicals
that pose an unacceptable risk to health or the environment. 226
Some of the information developed under REACH may be re-
quired to be disclosed to the EPA under the Toxic Substances
Control Act (TSCA). There is significant concentration and
integration between the European and U.S. markets with the nine top
chemical companies based in the U.S. 22 7 In 2006, U.S. chemical
exports to Europe were valued at over $45 billion, and imports from
Europe were valued at over $79 billion. 228 However, if chemical
companies initiate new chemicals in the U.S. before Europe, TSCA
does not necessarily require submission of data later submitted to the
EU. 229 Pre-manufacture notices of new chemicals must only submit
available data. However, TSCA does require that chemical compa-
nies report any information to EPA that reasonably supports a con-
221. Id. at 18.
222. Id. at 15.
223. Id. at 23.
224. Id. at 23-24.
225. Id. at 27.
226. Id. at 24.
227. Michael McCoy et al., Facts and Figures of the Chemical Industry, 85
CHEMICAL & ENGINEERING NEWS 27 (2007).
228. Id.
229. 15 U.S.C.S. § 2604(d)(B) (2008).
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clusion that a chemical presents a "substantial risk" of injury to
health or the environment.230
X. TSCA, EXISTING PROPOSALS FOR REFORM
As recognized in recent reports from the General Accounting
Office, TOSCA would require major changes to become effective to
protect against the risks of toxic chemicals. 231 The GAO's proposed
reforms are consistent with the recent legislative action in the Euro-
pean Union. In its August 2007 report, the GAO suggested that
Congress consider revising TSCA to place more of the burden on
industry to demonstrate that new and existing chemicals are safe,
and to set sjecific deadlines or targets for the review of existing
chemicals. The GAO suggested that some of the burden could be
shifted by requiring industry to test new chemicals based on substan-
tial production volume and the necessity for testing, and to notify
EPA of significant increases in production, releases, and exposures
or of significant changes in manufacturing processes and uses after
new chemicals are marketed.233
The GAO report does not specifically address the issue of con-
sumer warnings, or any possible expansion of TSCA that might in-
clude coverage for cosmetic products. Other issues that have been
discussed for recommended reform include a clarification of
concerns and priorities under the act to guide both the EPA and the
courts, a standard that the social benefits of a given chemical must
significantly outweigh its potential risk to both human health and the
environment in order for production to be approved, and substitution
230. 15 U.S.C. § 2607(e).
231. Statement of John B. Stephenson, supra note 193, summary of findings.
232. Comparison of U.S. and Recently Enacted European Union Approaches to
Prot. against the Risks of Toxic Chemicals, supra note 197, at 42-43.
233. Id. (The report also suggested that Congress take action to limit
confidentiality claims by clarifying that health and safety data cannot be claimed
as confidential business information, requiring substantiation of confidentiality
claims, limiting the length of time for which information may be claimed as
confidential without reaffirming the need the confidentiality, establishing penalties
for false filing of confidentiality claims, and authorizing state and foreign
governments to have access to confidential business information where they have
a legitimate need and can adequately protect against unauthorized disclosure).
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of the arbitrary and capricious standard of review for the substantial
evidence test.
234
On May 20, 2008, the Kid-Safe Chemicals Act235 was introduced
in the House. If ultimately passed, it would amend TSCA to reduce
exposure of children, workers, and consumers to toxic chemical sub-
stances. The proposed legislation is premised on the finding that "a
fundamental overhaul of chemical management in the United States
is needed to build a nontoxic environment for the children of the
United States. 236  However, the legislation as currently proposed
does not amend the definition of chemical substances regulated un-
der TSCA and thus would not apply to cosmetic products, or com-
ponents of those products. The proposal establishes safety standards
and requires the review of existing chemicals on a priority basis.237
The proposal places the burden of proof on industry to establish that
the chemical substance meets the safety standard.238 Industry would
also be required to submit and update all reasonably available infor-
mation. 239 No new chemical substances would be allowed to be dis-
tributed in commerce unless the government determines that the
manufacturer of the chemical substance has established that the
chemical substance meets the safety standard.240
XI. NON-ESSENTIAL CONSUMER PRODUCTS, A CASE FOR CHANGE: A
Low RISK THRESHOLD, INDEPENDENT TESTING, AND DISCLOSURE
In the context of nonessential consumer products where vulnerable
populations are exposed to unknown risks, the procedural and
evidentiary standards are excessive, and the threshold for risk is
unreasonably high. The recent decision in Congress, voting in favor
234. Hanan, supra note 208, at 416-17 (also proposing mandatory testing of all
new chemicals that contain a potential risk to human health and the environment.
If a new chemical, presented to EPA in a PMN, is suspected of having any poten-
tial deleterious effect on human health or the environment from its intended or
possible uses, EPA should require adequate testing. EPA should vary the testing
standards to match the potential risk foreseen).
235. Kid-Safe Chemicals Act of 2008, H.R. 6100, 110th Cong. (2008).
236. Id. at § 2.
237. Id. at § 501(4), (5).
238. Id. at § 502.
239. See CRS summary on Kid-Safe Chemicals Act of 2008, H.R. 6100, 110th
Cong. (2008) http://thomas.loc.gov/cgi-binlbdquery/z?d110:HR06100:@@@D&
sunm2=m& (last visited Feb. 27, 2009).
240. Id.
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of a statute directly banning phthalates in children's products and
child care articles, 241 bypasses the procedural and evidentiary
hurdles, but only for phthalates, and only for certain products. This
is important legislation, but phthalates are not the only chemicals
potentially affecting our children, and this legislation does not
address the issue of phthalates from other sources, including
cosmetic products. A statutory approach requiring congressional
action to regulate toxins in consumer products on a chemical by
chemical basis is ultimately ineffective given the size of the toxic
universe and the possibility of multiple sources of exposure. As
discussed above, there are an estimated 87,000 chemicals awaiting
an evaluation of endocrine associated risks. 242 We have no system
in place to monitor which of these chemicals are making their way
into our children's toys and cosmetic products or their potential haz-
ard. As one commentator reflected:
[C]itizens are experimental subjects in that de factor they
become one of the main testing grounds for the toxicity
of products, but without having authorized or consented
to the exposures. Moreover, to the degree that actual
practice requires that human harm must be scientifically
demonstrated before regulatory action is justified and
exposures reduced or eliminated, citizens are guinea pigs
in the more robust sense.243
In this post-market regulatory system, it is our children who must
bear the cost of uncertainty until and unless it is resolved.
Proving toxicity and exposure is a difficult process. Animal
studies may take up to 7 years. 244 There may be questions as to the
241. CPSC Reform Act (Engrossed Amendment as Agreed to by Senate),
H.R.4040, 110th Cong. (2d Sess. 2008) http://thomas.loc.gov/cgi-bin/query/
F?c 110:5:./temp/-c1 OoTnEDz:e144115: (last visited Feb. 27, 2009).
242. U.S. E.P.A., Endocrine Disruptor Screening Program, http://www.epa.gov/
scipoly/oscpendo/pubs/prioritysetting/index.htm (last visited Feb. 27, 2009).
243. Carl F. Cranor, Symposium: Do You Want To Bet Your Children's Health
On Post-Market Harm Principles? An Argument For A Trespass Or Permission
Model For Regulating Toxicants, 19 VILE. ENvTL. L.J. 251, 313 (2008).
244. Id. at 283 (citing Carl F. Cranor, Toxic Torts: Science, Law and the Possi-
bility of Justice 96-97 (Cambridge Univ. Press, 2006) (providing description of
different types of epidemiological studies)). See also Kenneth J. Rothman &
Sander Greenland, Modern Epidemiology 73-74, (Lippincott Williams & Wilkins
2d ed. 1998) (discussing different types of epidemiological studies).
20091
40 FORDHAM ENVIRONMENTAL LAW REVIEW
comparability of exposure levels, and the comparative sensitivity of
animals and humans. It is difficult, if not impossible, to use
observations of dose-response correlations in animals to determine at
what level of exposure a person may be affected. 245 There is also
the difficult issue of possible multiple sources of exposure and the
potential interaction of different chemicals as they mix into the pool
of contaminated human blood. Even when some segment of the
human population has been exposed to a potentially toxic substance,
epidemiologists may be unable to determine cause and effect
relationships due to other factors that can adversely affect an
individual's health. Endocrine disrupting chemicals in particular are
hard to evaluate and animal studies may not be able to capture
behavior changes, intergenerational effects, or other subtle or
difficult to identify risks. The science related to measuring and
demonstrating endocrine disruption is relatively new and validated
testing methods are still being developed. Endocrine disrupting
chemicals defy the rules of classic toxicology. 246 They have been
identified as having an unusual U-Shaped dose response curve where
negative health effects increase as the dosage increases, but above a
certain dose, the effects diminish, possibly due to an overloading of
the hormonal system that causes it to "shut off," effectively reducing
or preventing the dysfunction.247 Further these chemicals can have
opposite effects at different stages of an organism's development,
and there may be no threshold effect, that is most hormones in the
blood stream occur in dilute concentrations and even very dilute lev-
els of endocrine disrupting chemicals can prove dangerous. 248 The
low dose problem makes it difficult to set permissible exposures, and
risk assessment is complicated by the fact that fertility or reproduc-
tive disorders are much more difficult to detect in laboratory animals
than cancerous tumors. 249  Further, because endocrine disrupting
chemicals are thought to have synergistic effects, chemical-by-
245. Howard Latin, Good Science, Bad Regulation, and Toxic Risk Assessment,
5 YALE J. REG. 89, 119 (1988).
246. Jason M. Vogel, Tunnel Vision: The Regulation of Endocrine Disruptors,
37 POL'Y ScI. 277, 281-82 (2004), available at
http://www.springerlink.com/content/q45q1618427p/?p=fd36e7ab7be0403c907e6
d4eed45392d&pi=14.
247. Id.
248. Id.
249. Noah Sachs, Blocked Pathways: Potential Legal Responses to Endocrine
Disrupting Chemicals, 24 COLUM. J. ENvTL. L. 289, 317 (1999).
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chemical screening might be inadequate. 250 Also complicated, is the
possibility of intergenerational effects. Diethylstilbestrol (DES), a
synthetic estrogen given to pregnant woman in the early 1970's
damaged the children's reproductive system and caused vaginal can-
cer later in lives of the children.25'
The controversy over BPA is informative as to the difficulty of
regulating endocrine disrupting chemicals and the importance of
clear standards and independent testing. Approved as a food contact
substance, 252 BPA has received more consideration than many other
chemicals in the marketplace, yet politics, risk thresholds, and uncer-
tainty have kept it on the market. The FDA has issued regulations
approving, for food-contact uses, several polymers (such as polycar-
bonate) and other substances made with BPA.253 Before new food
additives are placed on the market, a company must first prove to the
FDA that the food additive is safe for human consumption at the
intended level of use.254 According to the legislative history, the
relevant standard is one of "reasonable certainty in the minds of
competent scientists that the additive is not harmful to man or ani-
mal. 255 In this case, however, even when working with this rela-
tively conservative standard, the relevant question may be: whose
scientists?
250. Id.
251. U.S. E.P.A., Endocrine Disruptor Screening Program, What Are Endocrine
Disruptors?, http://www.epa.gov/endo/pubs/edspoverview/whatare.htm (last vis-
ited Feb. 27, 2009).
252. See generally 21 U.S.C.S. §§ 301-399 (2008); 21 U.S.C.S. § 321(s) (2008)
("The term 'food additive' means any substance the intended use of which results
or may reasonably be expected to result, directly or indirectly, in its becoming a
component or otherwise affecting the characteristics of any food (including any
substance intended for use in producing, manufacturing, packing, processing, pre-
paring, treating, packaging, transporting, or holding food; and including any
source of radiation intended for any such use).").
253. Citikids Baby News, Inc. v. City of San Francisco, No. CGC-06-457303,
at 9 (Cal. App. Dep't Super. Ct. filed Oct. 25, 2006) (Application for Preliminary
Injunction) [hereinafter Citikids] ("BPA has the chemical name 4,4'-
isopropylidenediphenol. It is identified in various forms and for different uses as
an approved direct and indirect food additive." (citing 21 C.F.R. §§172.105(a),
175.105, 175.300, 175.380, 177.1440, 177.1555, 177.1580, 177.1585, 177.1595,
177.1655, 177.2280, 177.2420, 177.2600, and 21 C.F.R. §178.2010)).
254. 21 U.S.C.S. § 348 (2008).
255. Report of the Senate Committee on Labor and Public Welfare, S. Rep. No.
2422, 1958 U.S.C.C.A.N. 5300., 5301; see also 21 C.F.R. section 170.3(i).
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In the case of BPA, industry has been accused of manufacturing
doubt as to its risk for some time.2 56 "A 2005 analysis of the BPA
literature revealed a clear pattern of bias in reporting results: the
funding source often determined the findings. Of 115 studies on
health effects of BPA, 94 government-funded studies conducted in
academic laboratories in Japan, Europe, and the United States found
adverse effects at low dose exposure. None of these studies funded
by industry reported adverse effects. 257 Responding to an inquiry
from a California Assemblyman in 2005, the FDA wrote:
FDA is aware of several reports stating that bisphenol-A
has estrogenic activity and that, in spite of evidence that
bisphenol-A is harmless when consumed by animals in
amounts far (orders of magnitude) higher than humans
would consumer, such estrogenic activity persists at very
low doses. However, other reports appear to dispute any
reason to expect harm at the low exposures that humans
experience. FDA continues to closely follow the research
in this area. However, based on all the evidence available
at this time, FDA sees no reason to change its long-held
position that current uses with food are safe.258
In 2006, the National Toxicology Program's Center for the Evalua-
tion of Risks to Human Reproduction (CERHR) published a draft
advisory panel report that was heavily criticized by scientists for
having failed to include important studies, and inappropriately dis-
counting the value of others. 259 The report was allegedly written
largely by an outside consultant hired by the National Institute of
Health (NIH) who was fired in 2007 after public disclosure of its
conflicts of interest with the regulated industry. 260 Yet, still in Feb-
ruary 2008, the FDA was relying on only two studies, both spon-
sored by the American Plastics Council to base its decision as to the
256. See BREAST CANCER FUND, STATE OF THE EVIDENCE (2008), supra note
67, at 52.
257. Id.
258. Citikids, supra note 253, at 10 (citing letters from FDA (Apr. 6, 2005 &
Nov. 28, 2005)).
259. Jane Houlihan et al., Timeline: BPA from Invention to Phase-Out, ENVTL.
WORKING GROUP, Apr. 2008, http://www.ewg.org/reports/bpatimeline (citing
NAT'L TOXICOLOGY PROGRAM, DRAFr EXPERT PANEL REPORT (2006),
http://cerhr.niehs.nih.gov/chemicals/bisphenol/Bispehnol-ADraftReport.pdf).
260. Id
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safety of BPA. 261 FDA has held to this position despite the 2007
report released from a panel sponsored by the National Institute of
Environmental Health Sciences (NIEHS), a division of the National
Institutes of Health (NIH).262 The panel, composed primarily of
academic investigators specialized in BPA research concluded that
the "wide range of adverse effects of low doses of BPA in laboratory
animals [within the range of human exposure] exposed both during
development and in adulthood is a great cause for concern with re-
gard to the potential for similar adverse effects in humans." 263 The
panel explained that "BPA alters 'epigenetic programming' of genes
in experimental animals and wildlife.... These organizational ef-
fects... persist into adulthood, long after the period of exposure has
ended. Specifically, prenatal and/or neonatal exposure to low doses
of BPA results in organizational changes in the prostate, breast, tes-
tis, mammary glands, body size, brain structure and chemistry, and
behavior of laboratory animals."
264
Following the release of a new National Toxicology Program re-
port, Representative John Dingell, Chairman of the Committee on
Energy and Commerce, called on FDA to reconsider the safety of
BPA in products for infants and children. 265 In its draft report re-leased in Spring 2008, the National Toxicology Program concluded:
The scientific evidence that supports a conclusion of
some concern for exposures in fetuses, infants, and chil-
dren comes from a number of laboratory animal studies
reporting that "low" level exposure to bisphenol A during
development can cause changes in behavior and the
brain, prostate gland, mammary gland, and the age at
which females attain puberty. These studies only provide
limited evidence for adverse effects on development and
more research is needed to better understand their impli-
cations for human health. However, because these effects
261. Id. (citing letter from Steven R. Mason, Acting Assistant Commissioner
for Legislation, to Congressman John D. Dingell, Chairman of Committee on En-
ergy & Commerce (Feb. 25, 2008), available at http://energycommerce.house.gov/
Investigations/Bisphenol.022508.resptoO 11708.HHS.ltr.pdf).
262. Frederick S. vom Saal et al., supra note 26.
263. Id. at 136.
264. Id. at 134.
265. Committee on Energy and Commerce, News Release, May 6, 2008, avail-
able at http://energycommerce.house.gov/Press_1 10/1 10nr277.shtml.
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in animals occur at bisphenol A exposure levels similar to
those experienced by humans, the possibility that bisphe-
nol A may alter human development cannot be dis-
missed.
2 66
Despite this finding that there is cause for concern, on August 15,
2008, FDA issued a draft assessment reaffirming its finding as to the
safety of BPA for use as a "food additive." 267 Whether this will be
the final position of the government on this matter is unclear at this
point. The ongoing nature of controversy is reflected in the Wash-
ington Post's recent reporting that this finding stands in contrast
more than 100 studies performed by government scientists and uni-
versity laboratories finding health concerns associated with BPA.268
Without a clear and conservative definition of "safe," and adequate
testing and labeling standards, the U.S. regulatory system is creating
an unacceptable burden on the unknowing consumer. In the context
of non-essential consumer products where there is a significant
potential for a toxic exposure, some cause for concern ought to be
enough to restrict use of the chemical pending further study as to its
safety. Testing standards are especially important in face of the cur-
rent disincentives for industry to engage in testing considering, cost,
time, and potential litigation and reporting requirements.2 6 The
long delay from exposure to injury and the difficulty of linking latent
adverse effects with the product and its manufacturer create a
situation where the market is not likely to discriminate between a
tested and an untested product. We must also require that the
testing be done by independent companies. Congress, in the recent
CPSC Reform Act,271 recognized this need for mandatory third party
266. NATIONAL TOXICOLOGY PROGRAM, DRAFT NTP BRIEF ON BISPHENOL A,
37 (2008), available at http://energycommerce.house.gov/Press_110/Draft
NTPBriefonBPA.041408.report.pdf.
267. Christopher Lee, FDA Draft Report: No Risk from BPA in Food Contain-
ers, WASH. POST, Aug. 16, 2008, at A02 (citing NATIONAL TOXICOLOGY
PROGRAM, DRAFT NTP BRIEF ON BISPHENOL A (2008)).
268. Id. (noting "studies linking the chemical to prostate and breast cancers,
diabetes, behavioral disorders such as hyperactivity and reproductive problems in
lab animals").
269. See Wendy E. Wagner, Choosing Ignorance in the Manufacture of Toxic
Products, 82 CORNELL L. REv. 773, 784-88 (1997).
270. Id. at 784.
271. See CPSC Reform Act (Engrossed Amendment as Agreed to by Senate),
H.R.4040, 110th Cong. (2d Sess. 2008).
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testing for children's products, but as discussed above, only in the
limited context where there is a Consumer Product Safety
Commission rule, ban, standard, or regulation already in place.z72
We must now expand this standard.
When people are making choices to buy nonessential consumer
products, they are weighing the cost in dollars and the benefit of the
product. Any health risk hidden in the equation is not being bal-
anced by the consumer. In the case of cosmetics, in addition to a
direct risk to children from the use of these products, the risks may
also be disproportionately born by women of child bearing age and
thereby pose a risk to fetuses and nursing infants. In the case of toys
and child care articles, there is no doubt that the risk is dispropor-
tionately born by children. Consumers should not unknowingly be
subjected to chemical contamination from such products. It is wrong
and misleading to market products for children without disclosing
the possibility of toxic exposure to carcinogens, mutagens and endo-
crine disrupting chemicals. Where there is cause for concern, we
should take regulatory action. Given the difficulty of evaluating tox-
icity, and the capacity of industry to manufacture uncertainty, the
threshold for acceptable risk must be low, independent testing re-
quired, and any remaining risk clearly disclosed. As one commenta-
tor suggested, chemical invasions of our blood should perhaps be
considered a wrong, a "trespass" (regardless of whether they pose a
"risk"), with any resulting risks or harms viewed as additional
wrongs. 273
XII. CONCLUSION - POLICY RECOMMENDATIONS
It is clear that our system needs a major overhaul, and there are
economic benefits to achieving some consistency with the European
approach. According to the impact assessment on the European pro-
posal, overall costs for duplication of effort if cosmetic products are
developed for both the US and EU markets are 25% higher than for
developing products for only one of these markets. These costs
mount disproportionately if reformulation of a complex formula is
272. See id. at § 10.
273. See Cranor, supra note 243, at 252.
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required.274 Undoubtedly similar considerations apply to toys and
child care articles. We should develop our regulatory system with an
eye toward achieving some consistency. At the forefront, TSCA
should be amended to require premarket testing and review of new
chemicals, and testing of existing chemicals on a priority basis as
now required by Europe's REACH legislation. Since this effort is
already underway in Europe, the legislation should be drafted so as
to require review and sharing of information between Europe and the
USA. TSCA must also be extended to include coverage of chemi-
cals that will be used as components of cosmetic products. Data
gathered through this premarket testing program could be used to
establish a database that could later be used to help inform decisions
under the CPSA, the FHSA and the Cosmetic Act. These acts must
be amended to evaluate chemicals in products that may not yet have
been evaluated under an amended TSCA and to allow for a consid-
eration of the value of the consumer product to the consumer in rela-
tion to the risk it poses.
The European ban for identified, known and probable carcinogens
in cosmetic products should be generally replicated and extended to
include toys and child care articles in addition to cosmetics. The
current European proposal with the possibility for exceptions does
not seem unreasonable, as long as those exceptions do not override
the overall scheme, and the burden of proof is on the manufacturer.
As discussed in the European risk assessment, a ban may lead to in-
consistencies in regulatory regimes for different products. However,
we should not allow a toxin in a cosmetic product just because it has
not yet been banned under another regulatory regime. There may
also be arguments for a different regulatory standard where product
availability is important. In the context of toys and cosmetic prod-
ucts, the risk threshold should be low, commensurate with the socie-
tal value of the product, and the vulnerable populations potentially
affected.
As is currently proposed in Europe, we also must ensure that there
are clear standards as to required safety assessments, and a clear
definition of what will be considered "safe." The safety evaluation
should take into consideration only health, independent of any con-
sideration of cost to industry. Cost-benefit analysis here, where the
274. See COMMISSION OF THE EUROPEAN COMMUNITIES, WORKING PAPER:
IMPACT ASSESSMENT REPORT ON SIMPLIFICATION OF THE "COSMETICS DIRECTIVE"
supra note 122, at 16.
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human and societal cost is so difficult to evaluate and quantify, fa-
vors industry while unfairly burdening future generations. The
"unreasonableness" balancing test under the CPSA and TSCA,
which weighs the cost to industry, may find some justification in the
context of regulating consumer products that serve important
functions in our society, but it is generally inappropriate in the
context of toys and cosmetics. Where we are talking about nones-
sential products, we are talking about an industrial activity that we
don't need. We should not look at this as a loss, but as an opportu-
nity to redirect industry to create nontoxic alternatives, to shift re-
sources into another area that would be more socially productive.
Given the possibility for new formulations and products, it would
take a crystal ball to know whether there would in the end be any
significant cost to society in terms of jobs or economic loss follow-
ing the banning of hazardous substances in nonessential products.
At a minimum, consumers must be informed of any risk so that they
may make their purchasing decisions accordingly. Given rising can-
cer rates and other health concerns, we should, at a minimum, have
the choice to reduce our chemical blood burden and that of our chil-
dren where it is relatively easy to do so.
Following the European approach to cosmetic regulation (with the
proposed amendment to the absolute ban for category 1 and 2
chemicals), we should consider a conditional ban on known,
probable, and also possible human carcinogens, human neurotoxins,
and human developmental or reproductive toxins in children's toys,
childcare articles, and cosmetics that may be absorbed, inhaled or
ingested, unless the government can make an affirmative finding of
safety. If the government must find support for an affirmative find-
ing of safety before allowing the product on the market, the substan-
tial evidence rule would work in favor of consumer protection. In
the absence of substantial evidence as to safety, we should remove
the chemicals from the market. Given the difficulty of establishing
acceptable daily intake, and evaluating all sources of exposure, and
the importance of protecting all children (including those who may
mouth toys more than others), we should consider a higher thresh-
old, a presumption against a finding of safety for known and prob-
able carcinogens, mutagens and endocrine disrupting chemicals.
Proof should be required beyond a reasonable doubt. In cases where
only "possible" carcinogens, mutagens and endocrine disrupting
chemicals may be absorbed, inhaled or ingested, we could remove
the presumption against a finding of safety, but still require "reason-
able certainty" that there is "no cause for concern." In such cases,
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we should not equate this finding with one of safety, but recognize
the uncertain nature of the risk. Where there is a potential exposure
to possible carcinogens, mutagens and reproductive toxins, we
should require a finding that the societal value of the product to the
consumer exceeds the potential risk. In the end, however, the choice
should be that of the consumer. In all cases, there should be full dis-
closure of potential exposure to any chemicals that may cause can-
cer, reproductive harm, or mutagenicity, including all known, prob-
able and possible carcinogens and endocrine disrupting chemicals.
This notice should apply where there is a potential for exposure, re-
gardless of any findings as to safety. We should reject the unin-
formative type of generic warning. The notice should provide in-
formation to the consumer that, in using the product, potentially
toxic chemicals may be ingested, inhaled or absorbed (as the case
may be) and increase the risk of cancer, reproductive harm or
mutagenicity. The warning should be explicit as to any risk to chil-
dren and woman of child bearing age.
In the interest of the consumer, we should consider a substantial
pre-market review process with independent testing required. The
European proposal for cosmetic regulation with a pre-market toxicity
assessment requirement, coupled with the possibility of post-market
enforcement is an interesting proposal. This would perhaps operate
similarly to our tax system where review is threatened, but not guar-
anteed. Success may depend on the resources committed to the pro-
gram. However, given the obvious superiority from the standpoint
of consumer protection of a premarket approval process, this possi-
bility should be more closely evaluated. In rejecting a formal pre-
market approval scheme for cosmetics, the EU legislative report ex-
plains that the disproportionate risk posed by cosmetic products does
not justify such a regulatory approach given the following factors:
cosmetic products are not intended to be ingested, inhaled or in-
jected, a premarket approval system would be highly burdensome
both for regulators and the industry considering the 60,000 new
product formulations a year on the EU market; it would be a hin-
drance to innovation and to new products entering the market; and
this approach would run counter to other international regulatory
systems.275 However, even though cosmetics are not ingested, in-
haled or injected, they may be absorbed into the body. We should
not so quickly dismiss the uncertain risk of nonessential products;
275. Id. at 35.
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indeed the very purpose of the regulatory scheme is to evaluate that
risk. We must also consider the other side of the equation. Cos-
metic products and toys may pose a lesser risk that some other prod-
ucts like food contact substances, but they may also be less impor-
tant products. In reducing our risk to chemical exposure, we must
ask whether the product is important enough to risk its potential con-
tribution to our chemical burden and that of our children.
The cost to industry may not be extreme. The European cosmetic
proposal discussed the fact that REACH is going to ease access to
information on chemicals as 70% of all cosmetic ingredients are go-
ing to be affected by its registration/information obligation as they
are produced in quantities greater than 1 ton per year. To further
reduce the regulatory burden, we could consider the possibility of
creating an abbreviated process for the review of new formulations
that include chemicals or mixtures that have already been subject to
review. Although the European cosmetic legislative impact assess-
ment notes that there are 60,000 new cosmetic formulations a year, it
does not disclose the extent to which they differ. Safety determina-
tions could perhaps be split into different levels of review as appro-
priate. A very basic or "minimal" level of research might consist of
one or more short-term laboratory tests designed to determine if a
product is likely to constitute a serious hazard.277 Consideration
should be given to EPA's Endocrine Disruptor Screening Program
which uses a tiered approach for determining whether a substance
may have an effect in humans that is similar to an effect produced by
naturally occurring estrogen, androgen, or thyroid hormones. The
program includes standards for Tier 1 Screening, Tier 2 Testing, and
278hazard assessment. EPA has recognized the importance of re-
viewing chemicals in establishing this program. However, without
shifting more of the burden to industry to complete the review and
analysis of suspected endocrine disrupting chemicals, we are moving
forward at a snail's pace. In all fairness to the next generation, we
276. Id. at 43-44.
277. See Wagner, supra note 269, at 780-82 (noting the availability of testing
standards that have already been created by governmental bodies); see also,
Meghan E. Gallagher, Toxicity Testing Requirements, Methods and Proposed
Alternatives, 26 ENVIRONs ENvTL. L. & POL'Y J. 253 (2003).
278. U.S. EPA, Endocrine Disruptor Screening Program, EDSP Phases,
http://www.epa.gov/endo/pubs/edspoverview/components.htm#l (last visited Feb.
27, 2009).
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must move for reform to shift the burden away from the unknowing
consumer to the industry profiting from the uncertainty.
